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ABSTRACT
Buruli ulcer is a necrotizing skin infection and is the third most important
mycobacterial disease in immune competent individuals after tuberculosis and leprosy in
humid tropical countries. The causative agent, Mycobacterium ulcerans is unlike other
mycobacterial pathogens in that it appears to maintain an extracellular location during
infection. Another unusual feature of the bacterium is that it is the only mycobacterium
known to produce a dermo-necrotic polyketide toxin called mycolactone. A single Buruli
ulcer, which can cover 15% of a person's skin surface, contains huge numbers of
extracellular bacteria. The infection is characterized by massive necrosis at the site of
infection followed frequently by debilitating disfiguration. Despite their abundance and
extensive tissue damage, there is a remarkable absence of acute inflammatory response to
the bacteria, and lesions are often painless. Though there is extensive literature on
interaction of other mycobacterial species with innate immune cells, information
concerning interaction of M ulcerans with macrophages and neutrophils is scarce and
requires further investigation. Research in this dissertation was geared towards
understanding the poor innate immune response generated following M ulcerans
infection.
One hallmark of most diseases caused by mycobacteria including M tuberculosis,
M bovis, M leprae, M marinum, M haemophilum is the ability of the bacilli to grow
within host cells and cause granulomas. In contrast, M ulcerans primarily forms
extracellular microcolonies within necrotic tissues and is rarely found within host cells.
The role of mycolactone in the extracellular location of the bacteria was investigated
using a macrophage infection model. Experiments using a panel of mycolactone negative
IV
(myc-) and wild type (WT) M ulcerans strains showed that presence or absence of
mycolactone determines whether the bacteria are extracellular or intracellular. Exposure
of macrophages to high concentrations ofmycolactone interfered with their phagocytic
ability. These observations that a mycolactone mutant is better phagocytized than the
wild type strain is consistent with the presence of almost exclusively extracellular
bacteria in Buruli ulcer patients.
Experiments studying the effect of mycolactone concentrations on fibroblast cell
lines showed that mycolactone-mediated apoptosis and necrosis was concentration
dependent. Mycolactone caused necrosis at high concentrations and apoptosis at low
concentrations. Chemotaxis assays using human neutrophils showed that neutrophils do
not respond to M ulcerans (WT or myc-) or mycolactone. Mycolactone treatment
resulted in rapid necrosis of human neutrophils in a dose dependent manner in vitro.
These data could be relevant in vivo in human infections where toxin gradients produced
by a pool of extracellular M ulcerans may cause apoptosis or necrosis of inflammatory
cells trying to move into the focus of infection and clear the bacteria
Lack of an inflammatory reaction during the necrotizing stage of Buruli ulcer
could be due to abrogation of production of inflammatory cytokines (e.g. TNF-a, lL-l,
lFN-y), chemokines (IL-8) and lowered expression of cell-adhesion molecules (e.g.
lCAM-l, selectins, VCAM) which help inflammatory cells reach the site of infection.
TNF-a and lL-8 are key players in immuno-inflammatory responses. Studies regarding
TNF-a response to bacterial infection and mycolactone treatment in vitro showed that
WT M ulcerans and mycolactone did not induce TNF-a production while myc- M
v
ulcerans did. Interestingly, LPS mediated TNF-u production was inhibited by WT M
ulcerans and mycolactone. Both WT and myc- M ulcerans as well as mycolactone did
not induce IL-8 production. WT M ulcerans and mycolactone induced expression of the
cell adhesion molecule ICAM-I was less than that induced by myc- M ulcerans or LPS.
Microarray analysis of genes modulated by mycolactone yielded interesting
information. Genes that were significantly upregulated by mycolactone included those
related to transcriptional repressors, cytoskeletal rearrangement, cell cycle
control/proliferation, apoptosis, G-protein receptors, tumor supression and immune
response. Genes downregulated by mycolactone included those related to DNA repair,
inactivation of complement and metalloproteinases, immune response, leukotrienes
production, receptors for collagen and laminin. Data from the present study provide new
insight into the effect of mycolactone on macrophages, fibroblasts, neutrophils and host
gene-expression pathways induced or repressed by mycolactone. Knowledge obtained
from the present study can be expected to contribute to a better understanding of the role
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BACKGROUND AND RESEARCH OBJECTIVES
Introduction
The genus Mycobacterium is highly diverse, with 85 different species identified
since the identification ofMycobacterium leprae in 1873. The vast majority of
Mycobacterial species are environmental free-living saprophytes (1). Ofall the known
species of the genus Mycobacterium, only a few are known to cause disease in man [9].
Mycobacterial diseases cause substantial illness and death thoughout the worl<L
despite years of public health efforts. Mycobacterium ulcerans (M. ulcerans) is the
etiological agent ofBuruli ulcer (BU), the third most common mycobacterial infection of
immunocompetent humans after tuberculosis and leprosy (2). Buruli ulcer is the only
mycobacterial disease known in which a bacterial toxin, rather than a host response,
causes tissue destruction. The frrst cases of Buruli ulcer were described from central
Africa in 1897 although the fust African isolates were not cultured until 1964 (3). The
disease has since been recorded in many, mostly tropical countries in Africa. Central and
South America, Australia and Southeast Asia (4) (Fig. 1.1). In some West African
communities, BU has replaced tuberculosis (TB) and leprosy as the most prevalent
mycobacterial disease, affecting up to 22% ofthe population. However, the true global
impact of the disease is unknown because reliable tools for its rapid diagnosis and
surveillance are lacking (5). BU was recently recognized by the World Health
Organization as an important emerging disease (6).
I
Fig. 1.1. Countries where Buruli ulcer has been reported. Countries 
shown in red are endemic regions. (Taken from WHO Buruli ulcer 
website: http://www . who.intl gtb-buruli/ global_situation/index.html.) 
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Disease manifestation, transmission and therapy
BU is characterized by extensive tissue damage, which occurs in the absence of
an acute inflammatory response. There is considerable variation in the clinical
presentations of BU patients, and evidence suggests that there are geographical
differences in the severity and forms of the disease. Most researchers believe that M
ulcerans infection is acquired from the natural environment, and that small penetrating
injuries transmit the bacterium to the subcutaneous fat of exposed parts of the body. The
fIrst sign ofM ulcerans is a papule or pimple (like a spider bite) in the skin, with no
apparent involvement ofsubcutaneous fat (2) (Fig. 1.2). A characteristic BU has
scalloped edges and a base covered with necrotic slough. Although the mycobacteria are
concentrated in the center of the lesion, the ulcer is widely undermined, with vast
extension ofnecrosis into the subcutaneous fat.
Histopathologic examination reveals little acute or chronic inflammation in the
lesion, and M ulcerans is seldom seen in macrophages. Further, patients with BU
experience neither fever, malaise, nor regional lymphadenopathy. These features suggest
that toxin from M ulcerans exerts local immunosuppressive and/or antiphagocytic effects
(7). Histological specimens typically show large clumps of extracellular acid-fast
organisms surrounded by areas ofnecrosis and a poor or absent inflammatory response.
Later in the natural history of the disease, the immunosuppressive effect of the toxin is
somehow overcome by the host, immunity develops, and healing commences (8). An
intense necrosis is seen in the lesion but previously it was not clear whether this is
induced by the toxin or has an immunobiological basis (9).
3
stage 1(prt.Ulcentm 1btCt): 

1NIIIU1e, _Ie, Iftd ... 
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Fig. 1.2. Progression of Buruli ulcer lesion to the ulcerative stage, (Taken 
from van der WertI et ai., 1999) 
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Recent studies have shown that the tissue necrosis is, at least in part, due to the bacterial
toxin mycolactone. Widely used animal models to study the pathogenesis of M ulcerans
are mice and guinea pigs (10-13).
Lesions may occur on any part of the body though they are more common on
exposed parts, especially the limbs. Lesions are single, or less frequently multiple. Most
ulcers occur on the extremities and there is frequently a history of minor injury or insect
bite which fails to heal, or the spontaneous appearance of a small boil or papule which
becomes indurated, crusted, and eventually ulcerated (Fig. 1.3). Over a period of weeks
the ulcer enlarges, with widespread thickening of subcutaneous tissue. Subsequent
necrosis produces "undermining" of the ulcer margins, and a sharply defined ulcer edge
develops. The base of the lesion appears mucoid and there is frequently a clear serous
discharge. Where fat is exposed, it may appear white and lusterless. In large lesions there
is extensive induration adjacent to the ulcer. Beyond this area of thickening, however, the
skin appears normal with no cellulites, lymphangitis or lymphadenopathy. Without
therapy there is progressive enlargement, formation of satellite lesions, and necrosis
extending between lesions in subcutaneous tissue beneath apparently healthy surface
epithelium. Necrosis may extend down to muscle fascia and even to bone, but there is
seldom actual bone involvement. Irregular healing occurs with production of fibrous scar
tissue and calcification (14).
All the forms of disease-nodular, oedematous, plaque, ulcerative and
osteomyelitis are found among African patients. However, there also appears to be
geographical variation in the pathology of the disease. For example, the plaque form of
Buruli ulcer, though common in Benin, appears to be entirely absent in Australia.
5
Fig. 1.3. Buruli ulcer (A) Nodule (B) Ulcerative lesion. (Taken from 
Buruli ulcer: Diagnosis of Mycobacterium ulcerans disease, WHO 2001) 
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Osteomyelitis, which is fairly common in Benin and Ghana, has not been reported in
Australia or Mexico suggesting that M ulcerans isolates from outside West Africa may
be less virulent. Clinical data suggests that infections with Asian isolates may also be less
virulent than the African strains (3).
Neither the mode of transmission nor the environmental reservoir for M ulcerans
is known, although observational studies suggest that M ulcerans infection is transmitted
through the skin after contact with contaminated water, vegetation, or insects (5). The
organism has only been recovered from lesions of humans or, in one case, a koala, and
there has been only one report of person-to-person spread (15-16). Thus, environmental
exposure, either by direct inoculation or an insect vector, is the likely route of infection.
Epidemiologic studies suggest the proximity to water sources, such as freshwater lakes or
rivers, predisposes to disease, but specific contact with water that might lead to
transmission of the bacteria has not been identified. Cultures ofwater near BU-endemic
areas have not yielded M ulcerans, though testing of water samples by polymerase chain
reaction (PCR) detected M ulcerans in one Australian study. Soil also has been
considered a possible reservoir, but the organism has not been isolated or detected in soil
samples (17).
The most recent data regarding the environmental source of M ulcerans is the
detection and culture of M ulcerans from aquatic insects collected from the environment
in Benin by Portaels et al. (18). In another study, also in areas of Benin where BU is
endemic, it was shown that small fish were positive for M ulcerans by PCR (19).
Marsollier et al. (20) demonstrated that M ulcerans may multiply in the salivary glands
7
of aquatic insects following experimental infection and that bites of such insects
transmitted M ulcerans to laboratory mice.
BU is primarily a disease of children, with the highest rates found in children ages
2 to 14 years. Although reported in persons with human immunodeficiency virus (HIV),
no predilection for BU has been noted in mv-infected persons or other immunodeficient
patients (21, 22).
Culture and detection
M ulcerans is a slow-growing environmental mycobacterium that can be cultured
from human lesions on mycobacterial medium at 30-32°C (23). M ulcerans is
phylogenetically related to the ubiquitous waterborne M marinum, and can be
differentiated on the basis of phenotypic characteristics, slight nucleotide variations in
targeted genes, and the presence of two insertion sequences, IS 2404 and IS 2606 (24).
Confirmation ofBU disease can be performed with tissues obtained directly from the
excised skin or ulcer by combined laboratory methods such as Ziehl-Neelsen staining for
acid fast bacilli (AFB), bacterial culture, histopathology, and/or PCR (25).
Treatment
The treatment of BU depends on the stage of the disease. Chemotherapy has little
impact on the course of the disease and surgery is often required. Early lesions respond to
simple excision but ulcerative lesions require very extensive excision and skin grafting
(9). Pathologic changes that characterize early M ulcerans infections depend in large
measure on two distinct properties of the etiologic agent: (i) M ulcerans grows optimally
8
at temperatures lower than central body temperatures, Le., at 30 to 33°C, and (ii) M
ulcerans produces a toxin. This temperature growth requirement largely limits the
infection to body surfaces, and the toxin destroys tissue and suppresses local immune
responses (26).
Because lesions are painless, BU is rarely detected in an early and readily curable
stage. Most lesions are widely ulcerated when they are detected and require extensive
surgical excision and skin grafting. Primary culture ofM ulcerans under optimal
conditions may take several months (27). Traditionally, drug therapy has been considered
ineffective, but recent data suggest that combinations of antimycobacterial antibiotics that
include rifampicin and either streptomycin or amikacin are able to kill M ulcerans in
human lesions. The persistence of M ulcerans infection and ineffectiveness of antibiotics
are thought, at least in part, to relate to a local immunosuppression at the site of infection
(28). Untreated Buruli ulcer will eventually subside with the gradual development of host
immunity in most cases. However, by this time, tissue damage may be very extensive and
healing by scar can lead to permanent functional and cosmetic deformity (8). Recent
studies by Phillips et al. have shown that topical application of acidified nitrite increases
the rate ofhealing (29, 30).
Mycolactone-a major virulence determinant
Even though the better known pathogenic members of the genus Mycobacterium,
such as Mycobacterium tuberculosis (M tuberculosis) and Mycobacterium leprae (M
leprae), are not associated with toxins, the presence of a toxin in M ulcerans, which is an
extracellular pathogen, has been hypothesized for almost 40 years (31). Early studies by
9
Meyer et al. (32) have shown that M ulcerans secretes an exotoxin into culture filtrate.
The inoculation of concentrated culture ftltrate into guinea pig skin, causes inflammation,
necrosis, edema, and other histopathological changes which resemble infections of
humans (32-33). The resulting pathogenesis and histological appearance was explained
by a recently identified diffusible lipid toxin, mycolactone (3, 8).
Mycolactone was originally isolated, purified and characterized from M ulcerans
1615, a Malaysian isolate, as a mixture of cis/trans isomers designated mycolactone A
and mycolactone B (Fig. 1.4) (3). The discovery of mycolactone in M ulcerans is the
first report ofmacrolides from Mycobacteria species as well as the first identification of a
macrolide from any bacterial pathogen (34). Macrolides are an important class of
complex polyketides produced as secondary metabolites primarily by soil bacteria in the
order Actinomycetales (34). Mycolactone is a 12- membered ring macrolide which is the
group ofmacrolides containing the smallest lactone ring size. Well-known polyketides
include antibiotics (erythromycin), immunosuppressants (rapamycin, FK506), antifungal
agents (amphotericin B), antihelmetic agents (avermectin), and cytostatins (bafilomycin).
Other macrolides that induce apoptosis in tissue culture cells include erythromycin,
bafilomycin AI, antimycin A, and ionomycin (13).
The activity of mycolactone in vitro on cultured fibroblasts and macrophage cell
lines produces a distinct cytopathic phenotype. The earliest effect is cell rounding caused
by radical alterations in the cytoskeleton of cells, which occurs within 10 h after addition
of mycolactone to cultured cells. At 36 h, treated cells are arrested in Go/G. of the cell














L I I . Me 
/'V
II --: -:. . 
OH0 o~
~ 
Side Chain Encoded by mlsB 
Fig. 1.4. Structure of mycolactoneAIB. (Taken from Gunawardanna, et al. 
1999 and Song, B., and Kishi, Y., 2001) 
11 

a general inhibition of protein synthesis in response to mycolactone (35). In vivo studies
using a guinea pig model of infection suggest that mycolactone is responsible for both the
extensive tissue damage and immunosuppression which accompanies Buruli ulcer (36).
In another study, George et al. (13) demonstrated that injection of mycolactone into
guinea pig skin results in cell death via apoptosis and that the extent of apoptosis
increases as the lesion progresses.
A considerable body of evidence on in vitro and in vivo effects of macrolides is
present in the scientific literature. Macrolides modulate functions of inflammatory cells,
such as polymorphonuclear leukocytes, lymphocytes and macrophages. Among the most
important findings on macrolide interactions with phagocytes are their inhibitory effects
on oxidant production by stimulated cells and their modulation of pro-inflammatory and
anti-inflammatory cytokine release by these cells. Inhibitory effects of macrolides on
leukocyte chemotaxis have also been documented (37,38). Macrolides inhibit production
of proinflammatory cytokines including interleukin (IL)-l, IL-6, IL-8, and tumor necrosis
factor (TNF)-a, and inhibit expression of transcription factors, including nuclear factor
(NF)-KB and activator protein (AP)-l. Macrolides also inhibit neutrophil elastase and
reactive oxygen radicals; suppress expression of neutrophil adhesion molecules and
selectins, thus decreasing infiltration of inflammatory cells (39). Mycolactone could play
an important role not only in the immunosuppression and tissue destruction which occurs
in the disease but also in the ability of the organism to survive in an intracellular
environment (34).
Mycolactone appears to playa role in inhibiting recruitment of inflammatory cells
to the site of infection (40). The specific cellular effects of mycolactone suggest that
12
mycolactone might have therapeutic potential as an antineoplastic, anti-inflammatory
and/or immunosuppressive agent. Many bacterial toxins are proteins. These molecules
generally act either by forming pores in the host cell (hemolysins) and inducing cell lysis,
or by interacting with cell surface receptors thereby triggering a signal transduction
pathway within the cell which leads to intoxication (e.g. ADP-ribosylating toxins). Most
macrolides, however, are able to enter the host cell by passive diffusion and exert their
influence by binding directly to a cytosolic target. Snyder and Small (41) used a
fluorescent mycolactone derivative (bodipymycolactone) to determine whether
mycolactone interacted with a cell surface receptor and initiated a cell signalling cascade
which culminated in apoptosis or whether entered the cell passively and interacted
directly with internal targets. The same authors investigated the uptake and cellular
localization of mycolactone and showed that mycolactone entered cells by diffusion and
accumulateed in the cytosol (41).
Biosynthesis of mycolactone requires three polyketide synthase enzymes and at
least two accessory enzymes, all of which are located within a contiguous 11 O-kb cluster
on a large plasmid (8). The lactone core is encoded by two polyketide synthase genes,





In contrast to our knowledge of tuberculosis and leprosy, and despite the
frequency ofM ulcerans infection, there is a paucity ofknowledge about the human
immune response to M ulcerans. M ulcerans occurs in lesions primarily as extracellular
microcolonies (36). Unlike most other mycobacterial pathogens like M tuberculosis and
M leprae which are intracellular, M ulcerans infected tissues primarily contain
extracellular bacilli (AFB) in the center oflesions (17). Although lesions may be quite
extensive, covering up to 15% ofa patient's skin surface, they are relatively painless
(13). M ulcerans differs from M tuberculosis and M marinum in terms of tissue tropism
and phenotype of the host immune response. Whereas M tuberculosis and M marinum
disseminate in the host and proliferate within macrophages, M ulcerans is found almost
exclusively extracellularly in cutaneous and subcutaneous tissues (43) (Fig. 1.5).
Ashford et al. (44) and others recently reported that in Buruli ulcer disease
inflammation appears to be minor for the amount of necrosis. Connor and Lunn
hypothesized that the toxin may induce necrosis of the inflammatory infiltrate (31, 45).
Similarly, Pahlevan et al. have postulated that local secretion of mycolactone reduces the
cutaneous inflammatory response and may contribute to the development of the ulcer
(28) (7). These features suggest that the toxin from M ulcerans exerts local
immunosuppressive and/or antiphagocytic effects. Gooding et al. (46) showed that
patients with M ulcerans infection mount an immune response to M ulcerans as
14
Fig. 1.5. Cellular location of M. ulcerans (1) and M. marinum (2). 
1. Early-(A) and late- stage (B) disease histopatho- logic sections of the dermis 
stained for acid-fast bacilli (AFB) from a patient with a Mycobacterium ulcerans 
infection. In A, arrows indicate necrosis of adipose tissue distant from the location 
of AFB, and in B, the arrow indicates predominance of extracellular bacilli and 
microcolonies. Patients' samples were obtained from the study conducted in Cote 
d'Ivoire. 
2. A and B. Active disease histopathologic sections of soft tissue stained for acid­
fast bacilli from a patient with a Mycobacterium marinum infection. In A, the 
arrow indicates localized necrosis, and in B, the arrow indicates predominance of 
intracellular bacilli. 
(Taken from Dobos, K. M., et al. 1999). 
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evidenced by antibody production, but they demonstrate profound systemic T-cell anergy
to mycobacterial antigens (2). Pahlevan et al. (28) reported that the partially purified
mycolactone toxin had profound inhibitory effects on the elaboration ofTNF and IL-2 by
monocytes and T lymphocytes, respectively. The same authors proposed the toxin would
have potent inhibitory effect on a mounting immune-inflammatory response to M
ulcerans (28).
A hallmark of pathogenic mycobacteria is their capacity to establish chronic
infections in the host (43). With the exception ofM ulcerans, all other pathogenic
mycobacteria are considered intracellular parasites. Early studies by Rastogi et al. (47)
compared intracellular growth of various pathogenic (M paratuberculosis, M ulcerans,
M tuberculosis H37Rv, M kansasii, M bovis) and nonpathogenic mycobacteria (M
tuberculosis H37Ra, M bovis BCG, M gastrl). All mycobacteria with the exception of
M ulcerans and M gastri effectively multiplied inside J774-macrophages. Inability to
propagate M ulcerans inside J-774 macrophages was hypothesized to be due to a toxin
secreted by the bacteria inside macrophages leading to massive lysis after infection. J-774
model has been used extensively to study in vitro host-mycobacteria interactions (47).
The pathogenesis of M ulcerans is closely associated with expression ofmycolactone, as
a natural mycolactone deficient mutant failed to induce ulcers in guinea pigs (36).
Most pathogenic mycobacteria are primarily intracellular when residing in
vertebrate hosts. One of the oldest and most well-supported observations regarding the
interaction between pathogenic mycobacteria and the macrophage is the intracellular
location ofmycobacteria Macrophages produce various chemokines (e.g. RANTES and
MCP-l) and cytokines (e.g. TNF-a and IL-lf}) following a mycobacterial infection and
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these immune effector molecules are required for recruitment and activation of
leucocytes and subsequent control of the mycobacterial infection. In particular, activation
of macrophages by stimulated T cells is thought to playa critical role during
mycobacterial infection and results in increased expression of antimycobacterial
mediators such as reactive nitrogen intermediates. The ability to limit production of
inflammatory mediators suggests that pathogenic mycobacteria like M ulcerans initiate
an active process to manipulate the macrophage signal transduction pathways. A major
potential mediator of upstream signaling events is mobilization of calcium. Ca2+ is
required for activation of protein kinase C and calmodulin kinase pathways, which are
both potential upstream activators ofmitogen activated protein (MAP) kinases (48). The
current understanding of macrophage signals initiated upon infection and how M
ulcerans modulates these signaling pathways is limited.
Adaptive immune response
During the necrotic phase ofthe disease, there is virtually no cellular response to
the infection. No skin-test reactivity to burulin (a skin-test reagent prepared from M
ulcerans organisms) develops in patients during this phase of the disease. Skin-test
reactivity is observed during healing and is accompanied by granuloma formation in the
ulcer bed and surrounding tissue. Pimsler et al. (49) speculated that healing begins to
accelerate when M ulcerans no longer produces toxin, thus permitting development of
the host response to other antigenic components of the etiologic agent (e.g., cell wall).
Suppression of immune responses is an important factor in the pathogenesis of several
mycobacterial diseases of humans. In susceptible individuals, infection by M leprae is
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accompanied by development of suppressor T cells that are M leprae specific.
Mycobacterium avium and Mycobacterium intracellulare infections are infrequent in
healthy individuals but are common and life threatening in immunodeficient patients with
AIDS. Pimsler et al. (49) reported that M ulcerans produced a toxin that prevented T cell
activation and suppressed phagocytosis by macrophage. Pahlevan et al. (28) showed that
high density lipid fractions from culture filtrates ofM ulcerans inhibited LPS-induced
TNF and IL-I0 production. These fractions also blocked production ofIL-2 from
activated T lymphocytes. Interestingly, TNF induced NF-KB activation was inhibited
whereas a synergy was observed between the factor and phorbol ester-directed NF-KB
activation (28).
Gooding et al. (7) postulated that T cell anergy to mycobacteria may contribute to
the pathogenesis of Buruli ulcer. Absence of a positive skin test response in most patients
may indicate that cellular immune responses are not or are only weakly induced.
Interestingly, spontaneous healing is often accompanied by skin test conversion, again
suggesting a pivotal role of the immune system in the control of the disease (50). BCG
vaccination had an incomplete but significant protective effect against Buruli ulcer in two
controlled trials in Uganda (2). No study has addressed whether cytotoxic or
immunosuppressive factors are released from M ulcerans during the early, active, or late
stages of infection; mechanisms by which such factors might act on host tissues are also
not known (17). In another study, Gooding et al. (7) reported marked anergy to M
ulcerans in patients with current or past M ulcerans-induced disease, comparable to that
to M bovis BCG observed in Mantoux test-negative subjects. They showed that the
anergy is not generalized, as evidenced by a normal proliferative response and IFN-y
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production following stimulation with PHA. This anergy was due to failure to recognize
M ulcerans, as antibodies to these bacteria were demonstrated in patients with unreactive
peripheral blood mononuclear cells (PBMe) but in none of the control subjects. The
same authors suggested that in individuals who develop overt disease, the bacteria are
ineffectively phagocytosed or escape from phagocytes before being killed, processed, and
presented to T lymphocytes (7).
Cytokine response
Phagocytic cells playa key role in the initiation and direction of adaptive T-cell
immunity by presentation of mycobacterial antigens and expression of costimulatory
signals and cytokines (51). IFN-y is a major factor in macrophage activation and plays a
critical role in protection against infection with mycobacteria. T-cell anergy and lack of
IFN-y production in patients with M ulcerans disease may account for the persistence of
extracellular mycobacteria, the indolent nature of the disease and its failure to respond to
conventional antimycobacterial chemotherapy (7, 52). In addition, inappropriate cytokine
production may divert immune systems of patients toward a predominantly Th2-type
response, thus, accounting for enhanced antibody responses of patients (46). Mycolactone
inhibits IL-2 production ofactivated lymphocytes, and TNF-a expression of LPS-
stimulated monocytes (28). A comparative analysis of systemic and intralesional cytokine
production in patients suffering from the nodular and ulcerative form of the disease
showed that patients with nodular forms demonstrated higher IFN-y and lower IL-l 0
production against M ulcerans than patients with ulcerative forms (53). IL-I0 is a well
known powerful downregulator ofIFN-y production (54). Other Th2 type cytokines that
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may be responsible for the low M ulcerans specific IFN-y response are IL-4, 5, 6 and 13.
Huygen et al. (55) hypothesized that mycolactone could stimulate production ofIL-lO in
the skin, which, in turn, would have a direct anti-inflammatory effect and downregulate
production of IFN-y by Th1 T-lymphocytes. Regulatory T-cells are possible candidates
responsible for elevated production ofIL-lO, since another cytokine produced by
regulatory T-cells, i.e., transforming growth factor (TGF)-~, is also produced by PBMC
cultures from BU patients stimulated with M ulcerans bacilli (55). Recent studies by
Westenbrink et al. (56) showed that early-stage BUD patients produced significantly
lower levels ofIFN-y and IFN-y/IL-4 ratios compared to late-stage BUD patients after
PHA stimulation. Compared to that of controls, IFN-y production after tuberculin
stimulation was significantly higher in late-stage but not in early-stage BUD patients. The
same authors concluded that differences in Th-l-type cytokine production between early-
and late-stage BUD might reflect an improved immune defense over time (56).
Humoral response
Significant immunoglobulin (lg)G antibody production against M ulcerans can
be demonstrated in both patients and in unaffected household contacts, as tested by
immunoblot analysis with extracts of M ulcerans. This antibody production in unaffected
contacts may be related to the extracellular localization ofM ulcerans, even in the early
forms of infection (25). It forms a marked contrast with the serological findings for
tuberculosis and leprosy, in which only patients with advanced disease display significant
antibody production against the pathogen that is initially confined to an exclusive




(MUCF) antigens cannot distinguish between diseased, healed or healthy individuals in
endemic regions. On the other hand, primary IgM antibody responses against these
MUCF proteins can be detected in sera from 85% of confirmed BD patients and only in
4.5% sera from healthy family controls. From a group of 56 patients who were IgM-
positive to MUCF antigens, 21 patients were at the early nodular stage, while 35 were at
the later ulcerative stage (25).
Vaccine
Currently, there is no specific vaccine against M ulcerans but evidence in the
literature suggests a cross-reactive protective role of the M bovis BCG vaccine used
against tuberculosis. Although BCG vaccination seems to offer short-term protection
against the development of BD, it does not seem to influence actual incidence of BD in
the long run (59,60). Mycolactone-negative isolates of M ulcerans have been identified,
both as spontaneous mutants that lack yellow pigmentation and more recently by
screening of kanamycin resistance in isolates generated by transposon mutagenesis.
These mycolactone-negative mutants may offer a better and more specific protection than
BCG. Mycolactone is an obvious candidate for a vaccine but by virtue ofits chemical
structure, a polyketide is not in itself immunogenic (55). So far, antibodies against
mycolactone have not been detected either in healthy contacts or in BD patients. A key
question which may be essential for the development of an effective vaccine: is M
ulcerans intracellular or extracellular during the early stages of infection?
A number of mycobacterial lipids have been postulated to playa role in
pathogenesis and have multiple effects on host cells, particularly immune cells. The lack
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of an acute inflammatory response to infection with M ulcerans, the cytopathology of the
toxin on tissue culture cells, and the lipid nature of the toxin suggest that the M ulcerans
toxin may function in a unique, as yet uncharacterized mechanism (35). The most
distinctive feature ofM ulcerans pathology is the presence of cell damage in the absence
of an acute inflammatory response. Apoptosis as a phenomenon is associated with a lack
of inflammatory response. If apoptosis is a major cause of pathology in Buruli ulcer, this
could explain why an acute inflammatory reaction does not develop in Buruli ulcer
lesions despite extensive cell damage. Mycolactone as a single molecule might lead to
this property (13).
In M ulcerans infection, as in other mycobacterial infections (eg, M
tuberculosis), the immune system may fail to recognize common mycobacterial antigens;
this failure facilitates disease progression (2). Loss of protective immunity could be
innate, acquired from environmental pressure, or induced by M ulcerans infection itself
(40). The immune mechanisms involved in protection against Buruli ulcer are largely
unknown at present. A better definition of cellular immune responses to M ulcerans may
have an important impact on vaccine development (7, 46, 52).
Research objectives
Though there is extensive literature on interaction of other Mycobacterial species
with innate immune cells, information concerning interaction of M ulcerans with
macrophages and neutrophils is scarce and requires further investigation. Bacterial
resistance to phagocytosis may represent a pathogenic strategy for successfully
establishing disease. This characteristic ofM ulcerans may be relevant in vivo for
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maintenance of skin lesions and bacterial persistence in tissues or ulcers. Specific
virulence factors that might be responsible for inhibition of phagocytosis and
subsequently extracellular location of the bacilli have not been identified. Understanding
the response of innate immune cells to M ulcerans may provide insights to host defenses
and tactics used by the pathogen to circumvent these defenses.
Phagocytosis constitutes the primary line of host innate defense against incoming
microbial pathogens, providing an efficient means for their removal and destruction.
Phagocytic cells such as granulocytes, monocytes, and macrophages, defend against
different pathogens by ingesting and killing invaders. However, several virulent bacteria
have evolved mechanisms to prevent their phagocytosis as part of their pathogenic
profile. Such mechanisms allow the organism to block phagocytic responses and in some
instances to avoid destruction via degradative endocytic pathways, thereby impairing
development of cellular immunity and enhancing extracellular survival (61). How
microorganisms are phagocytosed and killed, and why certain pathogens resist these
mechanisms, are crucial questions for an understanding of the pathogenesis of infectious
diseases and development of innovative treatment approaches.
In order to better understand the poor immune response generated following M ulcerans
infection, the following hypotheses were tested:
• The diminished acute inflammation in early infection with M ulcerans may be
partially because the bacteria are ineffectively phagocytosed. Mycolactone, the M
ulcerans toxin, may paralyze macrophages rendering them incapable of
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phagocytosis. Cellular response to mycolactone may be dose dependent.
• Lack of an inflammatory reaction and recruitment of immune cells during the
necrotizing stage of Buruli ulcer could be due to abrogation ofproduction of
inflammatory cytokines and lowered expression ofcell adhesion molecules.
• Gene transcription profiling of cells treated with mycolactone may yield valuable
information that may give an insight into the pathway/s of action ofmycolactone.
To test these hypotheses, our objectives were as follows:
1. Elucidate the kinetics and efficiency in vitro of phagocytosis of M ulcerans by
macrophages and the capacity of the bacteria to survive within phagocytic cells.
2. Examine the effect ofmycolactone on the cellular and immunological responses
to M ulcerans by comparing wild type (Wl) M ulcerans with an isogenic
mycolactone negative mutant.






Bacterial and yeast cultures
A well characterized clinical isolate, Mycobacterium ulcerans 1615 (ATCC
35840; ATCC, Manassas, VA) (62) (36) isolated originally from a Malaysian patient,
was obtained from the Trudeau Collection (Trudeau Institute, Saranac lake, NY) and used
as wild type (WT) strain in all studies. MU 1615A was isolated as a nonpigmented,
spontaneous mutant from MU 1615 and characterized by mass spectroscopy, PCR
analysis and cytopathicity assays (36). PCR analysis using probes to the mycolactone
plasmid and mycolactone genes (63) showed that loss of mycolactone production in this
isolate occurred due to plasmid deletions in which partial deletion of mlsA and absence of
mlsB resulted in loss of mycolactone production (Fig. 1.1). Deletions in this portion of
the plasmid have been reported recently in other isolates (64).
The mycolactone core lactone is encoded by mlsA and the fatty acid side chain by
mlsB (42). Transposon mutagenesis was used to generate strains with insertions in
polyketide synthase genes, mlsA and mls. Because of the extreme redundancy in the
mycolactone gene sequence, mass spectroscopic analysis was used to determine whether
a particular transposon insertion had occurred in mlsA or mlsB (64). Although the loss of
mlsA results in total absence .of mycolactone, core lactone lipid was detected in strains
MUI615::Tn84, MUI615::Tn94 and MUI615::TnlOO confIrming that these isolates
contain insertions in mlsB. Mass spectroscopy analysis and cytopathicity assays were
used to confIrm the absence of mycolactone in all mycolactone negative mutants (myc-).
Mycobacterial strains were grown in Middlebrook 7H9 medium (Difco, Detroit, MI)
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supplemented with 10% oleic acid-albumin-dextrose enrichment (OADC) and
Middlebrook 7HIO agar (Difco, Detroit, MI) and incubated at 32°C. OADC was prepared
with bovine serum albumin (BSA; Sigma, St. Louis, MO) and all other reagents (Fischer
Scientific, Pittsburg, PA). Candida albieans SC 5364 was grown overnight in yeast
extract potato dextrose (YEPD; Difco, Detroit, MI) medium at 30°C.
Cell culture
1774A.I mouse macrophage cells (ATCC TIB 67), L929 mouse fibroblasts
(ATCC CCLI) and THP-I human monocytes (ATCC TIB-202) were purchased from
American Type Culture Collection (ATCC, Manassas, VA) and maintained in Dulbecco
modified Eagle medium (DMEM, Mediatech Inc.) supplemented with 2mM L-glutamine
(Bio Whittaker) and 10% (macrophages, monocytes) or 5% (fibroblasts) heat inactivated
fetal calf serum (FCS, Mediatech Inc.) at 37°C in a humidified atmosphere containing
5% CO2•
Bacterial uptake assay
Mouse macrophages (1774, IOscells/ml) were grown overnight in a 24-well plate
and infected with wr and mycolactone mutant strains of M uleerans. Mycobacteria were
passed through a 25-gauge needle 10 times to break up clumps, and 1O~1 of the
suspension were added to each well to give a multiplicity of infection (MOl) of
approximately 10 bacteria: I macrophage (quantified by plating dilutions of inoculum).
Plates were centrifuged at 1500rpm for 5 min to facilitate contact between bacteria and
adherent macrophages. Phagocytosis was allowed to occur at 37°C, 5%C02. After 24 h,
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infected monolayers were washed with phosphate-buffered saline (PBS), lysed with
0.01% sodium dodecyl sulfate (SDS; Fischer Scientific) and plated. Plates were
incubated at 32oCfor 6 weeks and percentage of inoculum internalized was determined.
Samples were tested in triplicate and repeated at least twice.
Intracellular survival assay
Cells were infected as described in the bacterial uptake assay. After 8 h, the
supernatant was removed, cells were washed to remove non-adherent bacterial cells and
fresh tissue culture medium with 100 Ilg/ml of amikacin was added. Cells were washed
every two days and tissue culture media containing 20 Ilg/ml ofamikacin was added. At
1,3, and 6 days following infection, macrophages were lysed with 0.01%SDS, the lysate
was diluted ten-fold and plated on M7H10 agar supplemented with 10% OADC. Plates
were incubated at 32°C for 6 weeks and colony forming units (CFUs) were determined.
Samples were run in triplicate and repeated at least twice.
Inhibition of phagocytosis
Murine macrophages (J774) were treated with mycolactone, 10ng/ml, 400ng/ml
or 7.9/lg/ml, for 12 h. C. albieans was then added at a MOl of 10:1. After 3 h, the
supernatant was removed and cells were washed with PBS. After lysis of cells with
0.01 % SDS, lysate was diluted ten-fold and plated on YEPD agar to determine the
percentage of inoculum internalized. Plates were incubated at 30°C for 24 h and CFU
were determined. Results are from triplicate samples from a typical experiment.
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Neutrophil chemotaxis asays
Peripheral blood neutrophils were isolated from 30 ml of human blood sample
collected from the antecubital vein of a healthy individual using sodium citrate as
anticoagulant. The protocol for drawing blood from healthy volunteers was approved by
the institutional review board of the University ofTennessee (IRB # 6476B). Blood was
mixed with equal volume ofsaline and centrifuged for 30 minutes at room temperature in
a Ficoll-Histopaque discontinuous gradient (Mediatech, Herndon, VA). The upper layer
was discarded and the pellet was mixed with 20 m1 of 3% dextran, and centrifuged at 400
x g for 5 minutes. Neutrophils were recovered and contaminating erythrocytes were lysed
by hypotonic shock. Cells were washed and the pellet was resuspended at a concentration
of 5 x 106 cells/ml in fresh chemotaxis buffer (prepared from Hank's balanced salt
solution, Gibco BRL, Grand Island, NY; 0.1% BSA, Roche, Indianapolis, IN; and lOmM
HEPES, Gibco BRL). Neutrophils suspended in chemotaxis buffer were added to the
upper compartment ofa 96-well ChemoTx System chemotaxis chamber (NeuroProbe,
Inc., Gaithersburg, MD.).
For the study of chemotaxis, bacterial samples were added in 30 ~l chemotaxis
buffer to the lower compartment of the chemotaxis chamber. IL-8 served as positive
control. Plates were incubated for 1 h at 37°C under a 5% CO2 atmosphere. The number
of cells that migrated to the lower wells was calculated by counting 5 fields of triplicate
10 ~l aliquots on a microscope using a hemocytometer. Each experiment was repeated at




LDH release and apoptosis
L929 fibroblasts and peripheral blood human neutrophils were assayed for cell
death via apoptosis and necrosis. Cytotoxicity/necrosis was measured using a
colorimetric kit from Promega (Madison, WI) as described previously (65). Briefly, cells
were suspended in DMEM supplemented with 5% (fibroblasts) or 10% (neutrophils) FCS
and L-glutamine and were seeded at a concentration of 6 x 103 cells/well in a 96 well
plate. The release of the cytoplasmic enzyme, lactate dehydrogenase (LDH), from
mycolactone treated, permeabilized cells was measured 4 and 24 h post infection by
using the colorimetric kit from Promega and following manufacturer's instructions.
Background release of LDH was obtained by measurement of ethanol treated cells, and
maximum release ofLDH was obtained by lysis of untreated cells according to
manufacturer's protocol (Fig. 2.1). The percent LDH release was then determined using
the following calculation: [(release ofLDH from mycolactone treated cells-background
release from untreated cells)/(Maximum release ofLDH by cell lysis-background
release)] x 100.
Apoptosis was measured from mycolactone treated neutrophils and fibroblasts at
4 h and 24 h post treatment using the Cell Death Detection Plus enzyme-linked
immunosorbent assay (Roche) as described previously (Fig. 2.2) (65). Apoptosis was
then determined as fold enrichment of nucleosomes using the following calculation:
[(measurement of DNA-histone complex from treated cells / background measurement of
untreated cells)]. Samples were run in triplicate and repeated at least twice.
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The general chemical reactions of the CytoTox 96® Assay are as follows: 
LOH 
NAD+ + lactate ~ pyruvate + NADH 
Diaphorase 
NADH + INT ~ NAD+ + formazan (red) 
Fig. 2.1. Schematic showing the cytotoxicity assay 




streptavidln­ anti-histone sample anti-DNA · ABTS 
coated MTP biotin containing POD substrate 
nucleosomes 
Fig. 2.2. Schematic illustrating the ELISA assay used to 





Mycolactone was isolated from MU 1615 in late exponential growth phase as
described previously (3, 36, 66). Briefly, lipids were extracted from WT 1615 using
chloroform:methanol 2:1 (vol/vol) and phospholipids were removed by precipitation
with ice cold acetone. Purified mycolactone was obtained using a chromatotron
(Harrison, CA) as described previously and analyzed by running on a silica thin layer
chromatography (TLC) plate (Alltech, Deerfield, IL) in a solvent system of
chloroform:methanol:water (90:10:1). Lipids were visualized with eerie sulfate-
ammonium molybdate in 2 M sulfuric acid stain. Mycolactone was then tested in
triplicate on L929 murine fibroblasts for cytopathicity (CPA). This CPA phenotype has
been established previously as the minimal concentration of toxin per milliliter that
causes inhibition of cell growth by 24 h and 90% cell rounding with loss of the
monolayer by 48 h (13,35-36).
Enzyme linked immunosorbent assays (TNF-a, IL-8)
Human THP-1 cells seeded at 1x1OS cells/well were grown in a 24-well plastic
tissue culture plate and differentiated using phorbal 12-myristate-13 acetate (Sigma) (100
ng/ml). After 24 h, the supernatant was removed and fresh tissue culture medium
supplemented with 10% FCS and L-glutamine was added. Cells were stimulated with
wild type M ulcerans (1615), mycolactone negative mutants of M ulcerans (MU 1615A,
MU 1615::Tn119), Mfortuitum (MOl of 10:1), mycolactone (50 ng/ml, 400 ng/ml or 50
flg/ml), LPS (10ng/ml) or wild type M ulcerans and LPS (Sigma) (10ng/ml). Untreated
and ethanol treated cells served as negative controls. Culture supernatants of triplicates
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were collected 24 h post infection and used for quantification of secreted TNF-a and IL-8
by sandwich ELISA using commercially available antibody pairs according to the
manufacturer's instructions (BD Pharmingen, San Diego, CA). Briefly, culture
supernatants were added to TNF-a or IL-8 specific monoclonal antibody-coated wells
followed by biotinylated specific monoclonal secondary antibody. After incubation and
washing with PBS tween, strepavidin peroxidase was added. After incubation and
washing to remove unbound enzyme, a substrate solution (ABTS, 2,2'-Azino-di-(3-
ethylbenz-thiazoline Sulfonic Acid, Zymed, San Fransisco, CA) was added to induce a
colored reaction product. The intensity of the color reaction was measured at 405nm to
estimate the concentration ofTNF-a or IL-8 present in the culture supernatant. Sample
concentrations were calculated using a standard curve. Results were expressed as amount
of cytokine or chemokine in pg/ml. Data are expressed as means ± S.D. (n=3).
Intracellular adhesion molecule-l (ICAM-l) expression.
Human THP-1 cells seeded at 1x IDs cells/ml were grown in a 12-well plastic
tissue culture plate and differentiated using phorbal12-myristate-13 acetate (100 ng/ml).
After 24 h, the supernatant was removed and fresh tissue culture medium supplemented
with 10% FCS and L-glutamine was added. Cells were infected with WT M ulcerans,
myc- (mycolactone negative) M ulcerans (119, 1615A), mycolactone (100 ng/ml, 1000
ng/ml), LPS (10 ng/ml, 100 ng/ml), or mycolactone (100 ng/ml, 1000 ng/ml) and LPS
(10ng/ml). Uninfected and ethanol treated cells served as negative controls. Supernatant
was removed 24 h post infection and cells were washed 3 times with PBS. Cells were
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then incubated with diluted (1:200) fluorescein labeled anti-human ICAM-l antibody
(Leinco Technologies, St. Louis, MO) for 45 min at room temperature according to
manufacturer's instructions. Cells were washed 3 times with PBS tween to remove any
unbound antibody and percentage ofICAM-l positive-cells was determined using a
fluorescent activated cell sorter (FACS, BD FACScan, San Jose, CA) and analyzed using
CellQuest software.
Western immunoblot analysis of I-kB degradation/inhibition
J774 cells (1xl05) were grown in a 6-well tissue culture plate overnight. Cells
were exposed to LPS (20 ng/ml) for 15 or 30 min, mycolactone (100 ng/ml) for 1 h
mycolactone 1 h and LPS for 15 min or 30 min. Untreated and ethanol treated cells
served as controls. After the indicated time points, the supernatant was removed and cells
were washed 3 times with ice cold PBS. Cells were lysed with 100 1-11 of sample loading
and lysis buffer, boiled at 95°C for 5-10 min and stored at -20°C for future use. Cell
extracts (501-11) were then analyzed by sodium dodecyl sulfate/polyacrylamide gel
electrophoresis using a Mini Protean II gel apparatus (BioRad, Hercules, CA) according
to the method described by Laemmli (67). Stacking gels of 4% and resolving gels of
10%(acrylamide/bisacrylamide 30:0.8, National Diagnostics, Atlanta, GA) were used.
Protein samples in 3x sample buffer (prepared with 1M Tris-cl pH 6.8 204ml, 20% SDS
3ml, Glycerol (100%) 3m1, ~-Mercaptoethanol1.6ml, Bromophenol blue 0.006g, total
volume of lOml stored at 4°C) were electrophoresed at lOOV for 1-1.5 h.
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Gels were subsequently soaked in protein transfer buffer (9g Tris base. 43.2g
glycine suspended in 2.4L ddH20 and 0.6L methanol) for 15 minutes. Proteins were then
transferred onto Immobilon-P polyvinylidene difluoride membranes (PVDF. Millipore.
Billerica. MA). prewetted with methanol and soaked in protein transfer buffer. using a
semi-dry apparatus (Bio-Rad. Hercules, CA) set at 100V for 1.5 h. For western blot,
unbound protein sites on the membrane were fIrst blocked for 1 h in 5% NFDM in TBS-
Tween 20 (8g Nac!. 20ml 1M Tris Hc!. 1L ddH20. pH 7.6. 0.1% tween 20) with 0.1 %
sodium azide. IKBa was detected by incubating the membrane with primary antibody
(Santa-Cruz Biotechnology Inc.• CA) 1: 1000 dilution in 5% NFDM in TBS- tween 20
overnight at 4°C with gentle agitation. washed with TBS-Tween 20 three times for 10
min each time and incubated with secondary horse radish peroxidase-antibody (Santa-
Cruz Biotechnology Inc., Santa Cruz. CA) 1:1000 dilution in 5% NFDM in TBS-tween
20. Immunoblots were developed by addition of 15 mg 4-chloro-1-napthol (Bio-Rad)
dissolved in 5ml ice cold methanol and 15f..tl of ice cold 30% H202 in 25 ml Tris buffered
saline (TBS, 20nM Tris, O.5M NaCl, pH 7.2). Development was at room temperature for
30 min and was terminated by washing the membrane extensively with water. Protein
sizes were determined by comparison to a set of standards (Rainbow markers, Bio-Rad).
Coomassie blue visualization of proteins, SDS/PAGE was performed as described
previously. Gels were placed in Coomassie staining solution (0.5% Coomassie brilliant
blue R (Bio-Rad) in 50% dH20. 40% methanol, and 9.5% glacial acetic acid) and
incubated for 1 h. All unbound dye was removed by 3 to 5 washes with destaining
solution (50% dH20 2, 40% methanol and 10% glacial acetic acid).
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Statistical analysis
Data were analyzed by using Students t-test. Bars represent the mean ± standard
deviation of experiments performed in triplicate.
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Chapter 3
INTERACTION OF MYCOBACTERIUM ULCERANS WITH MACROHAGES,
FIBROBLASTS AND NEUTROPHILS
Introduction
Monocytes/macrophages and neutrophils represent two arms of the innate
immune response. Neutrophils are found in blood; however their site of action is the
extravascular space. Neutrophils actively migrate to the site of infection through a
process involving adhesion to vascular endothelium and chemotaxis towards the site of
infection. Macrophages are resident phagocytes found in many different organs (13, 51,
68). Monocytes, which are macrophage precursor cells, migrate from the blood towards
the respective tissues, where they differentiate into macrophages. Macrophages play key
roles in host defense by recognizing, engulfmg, and killing microorganisms. A key
element in the cellular machinery that allows phagocytosis is the actin cytoskeleton. It
has been known for a long time that disruption of the actin cytoskeleton by certain toxins
inhibits phagocytosis (69).
Pathogenic mycobacteria such as M tuberculosis and M leprae can survive and
grow within host cells, particularly macrophages. The initial response to macrophage at
the site of invasion is likely to playa key role in determining the outcome of the
interaction and the overall regulation ofthe ensuing, adaptive, response (70). Unlike most
other mycobacterial pathogens, such as M tuberculosis and M leprae which are
intracellular, M ulcerans infected tissues primarily contain extracellular bacilli, with
microcolonies containing large number of extracellular acid-fast bacilli (AFB) in the
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center of the lesions (17). Infection with mycobacterial pathogens elicits a strong
inflammatory response. In contrast, M ulcerans, the causative agent of Buruli ulcer, is
unique among human mycobacterial pathogens in that the bacteria are primarily
extracellular and there is a limited inflammatory response to the infection (4,35, 71).
Here I show that mycolactone is the major virulence factor that influences phagocytosis
of M ulcerans by macrophages.
A wide variety of pathogenic microorganisms have been demonstrated to cause
eukaryotic cell death, either as a consequence of infecting host cells or by producing
toxic products (72). Host cell death may impair normal organ function and lead to
associated signs and symptoms of disease. Microbial pathogens may improve their ability
to persist in infected hosts by causing death of cells required for host defense (73).
Pathogen-induced cell death may occur by a variety of complex mechanisms. Elucidating
the factors required by a pathogen to kill host cells is, therefore, critical to uncovering
mechanisms of pathogenesis. Understanding the process of dying may reveal why certain
cells may be more or less susceptible to pathogen-induced cell death and reveal novel
therapeutic targets. Furthermore, the mechanism of cell death may have significant
consequences in terms of the ensuing response to the dead cell by modulating
inflammation or influencing the immune response (74). Cell death is typically discussed
dichotomously as either apoptosis or necrosis. Apoptosis is described as an active,
programmed process of autonomous cellular dismantling that avoids eliciting
inflammation. Necrosis has been characterized as passive, accidental cell death resulting
froni environmental perturbations with uncontrolled release of inflammatory cellular
contents. Multiple types of death may be observed simultaneously in tissues or cell
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cultures exposed to the same stimulus. The local intensity of a particular initial insult may
influence the mechanism of demise taken by individual cells in a population (72).
Preliminary data indicated that WT M u/cerans are taken up less efficiently by
macrophages in comparison to myc- spontaneous mutants of M u/cerans. The purpose of
this study was therefore, ftrst to investigate whether M u/cerans can be taken up by
macrophages and second to further elucidate the role of mycolactone in the interaction of
M u/cerans with macrophages and netitrophils by using well characterized transposon
insertion myc- mutants. M u/cerans strains tested are listed in Table I. The results of this
study demonstrate that mycolactone inhibits the uptake of M u/cerans by macrophages.
Also described, for the first time is the effect ofmycolactone concentration on whether
the cell undergoes apoptosis or necrosis.
Results
Mycolactone inhibits macrophage uptake ofM. ulcerans
A partial explanation for the absence of detectable intracellular M u/cerans in
macrophages from tissue from Buruli ulcer patients might be that mycolactone is
antiphagocytic. To test this hypothesis, J774 murine macrophages were assayed for the
ability to internalize M u/cerans and three Mumyc-, MuI615::Tn84, MuI615::Tn94, and
MuI615::Tn119. Mumyc- were internalized in signiftcantly greater numbers than the
parental M u/cerans 1615 (Figs. 3.1, 3.2). The percentage of inoculum internalized for
the mutants was in the range of 10.0 - 90.0% compared with 0.7% for isogenic WT M
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Table 1. M ulcerans strain list.
Name of the strain Characteristics Source
M ulcerans 1615 Virulent wild type Trudeau Collection
strain
M ulcerans Mycolactone Small lab
1615::Tn84, M negative; insertion
ulcerans in polyketide
1615::TnlOO synthase gene mlsB





M ulcerans Mycolactone Small lab
1615::Tn90 negative
M ulcerans Mycolactone Small lab
1615::Tn94, M negative; insertion
ulcerans in polyketide
1615::TnI19 synthase gene mlsB
M ulcerans Mycolactone Small lab
1615::Tn96 negative
M ulcerans Mycolactone Small lab
1615::Tn97 negative; insertion
in FurA gene
M ulcerans Mycolactone Small lab
1615::Tn107 negative; insertion
element (lS2606)
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Fig. 3.1. Uptake of wild and mycolactone mutant strains of M 
ulcerans. 1774 cells were infected with wild and mycolactone mutant 
strains of M ulcerans (MOl 10:1). Data are expressed as percentage of 
total inoculum internalized after 24 h. MU1615 versus MUI615::Tn84, 
MUI615::Tn94 and MUI615::TnI19, P<0.22, 0.001 and 0.025 




























Fig. 3.2. Uptake of wild and several mycolactone mutant strains ofM ulcerans. 
1774 cells were infected with wild and mycolactone mutant strains of M 
ulcerans (MOllO: 1). Data are expressed as percentage of total inoculum 
internalized after 24 h. 
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uleerans. There were also significant differences between the macrophage uptake of
different Mumye-. MuI615::TnI19 was phagocytosed significantly (P<0.05) better than
the other two Mumyc-. This could be due to the fact that Mu1615::84 and Mu1615::Tn94
contain insertions in mlsB which encodes the fatty acid side chain of mycolactone and
may contain small amounts ofa truncated polyketide whereas Mu1615Tn:: 119 has an
insertion in mlsA and does not produce detectable mycolactone precursors. Macrophages
infected with WT M uleerans showed cell rounding, cell cycle arrest and detachment
while cells infected with myc- M ulcerans appeared normal as did control cells (Fig.
3.3). These results suggest that mycolactone has anti-phagocytic activities.
Exogenous myco)actone inhibits phagocytosis in a dose-dependent fashion
To further investigate the anti-phagocytic effects of mycolactone, mycolactone
treated macrophages were assayed for their ability to take up Candida albieans. In these
studies, C. albieans cells were added to macrophages which had been treated with 10 ng,
400 ng, and 7.9 "",g mycolactone for 12 h and the percent inoculum internalized was
determined by CFUs. Despite the fact that both 10 ng and 400 ng of mycolactone
drastically altered the morphology of macrophages, this did not alter their phagocytic
ability (Fig. 3.4). However, mycolactone did inhibit phagocytosis of C. albicans at a
concentration of 7.9 "",g. These results show that the antiphagocytic activity of
mycolactone is a characteristic of cell-free, as well as bacterial bound mycolactone but
only at high concentrations.
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Fig. 3.3. Effect of WT M ulcerans and myc- MU 

















10ng 400ng 7.9ug Control 
Concentration of Mycolactone 
Fig. 3.4. Effect of mycolactone pretreatment on phagocytosis of C. 
albicans by murine macrophage cell line (1774). Macrophages were 
treated with different concentrations of my col act one for 12 h prior to 
addition of C. albicans (MOl 10: 1). After 3 h cells were lysed and plated 
to determine percentage of inoculum internalized. Control versus 7.9 f-lg 




M. ulcerans mycolactone negative mutant survives within macrophages
In order to detennine whether mycolactone affected the ability ofM ulcerans to
survive within macrophages, 1774 cells were infected with WT M ulcerans and
MuI615::Tn84 for 6 d. At 2 d intervals, bacteria were recovered from lysed cells and
CFUs detennined. MuI615::Tn84 were recovered in greater numbers (Ps 0.01) than WT
M ulcerans at 3 and 6 d post-infection (Fig. 3.5). Monolayers infected with MU myc-
continued to grow and appeared healthy throughout the infection period. Similar results
were obtained with Mumyc- strains 1615A (data not shown). In contrast, infection with
WT M ulcerans resulted in destruction of over 90% of the monolayer by 2 d. However, a
minor population of attached cells was present throughout the infection. A few « 10) M
ulcerans could be detected in these cells by acid fast staining. This, as well as the
recovery of WT M ulcerans throughout the infection period, suggests that small numbers
of WT M ulcerans can survive within macrophages. As shown in Fig. 3.6, no difference
was observed in in vitro growth ofMU 1615 and MU 1615::Tn84 in M7H9 liquid broth
up to 15 wk as detennined by the number ofCFUs. These studies show that Mumyc- are
not cytotoxic and replicate within macrophages.
Mycolactone-mediated necrosis and apoptosis is concentration dependent
Early work defining the effects ofmycolactone on cells showed that the molecule
caused apoptosis at concentrations as low as 2 pg/ml (13, 36). However, the limited
availability of chemically pure mycolactone restricted investigations to the use of small
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Fig. 3.5. Intracellular survival of wild and mycolactone mutant strains 
of M ulcerans in 1774 cells. The intracellular survival ofWT M 
ulcerans 1615 and Mu1615::Tn84 (MOl 10:1) after 1,3 (P < 0.01) and 






















Fig. 3.6. Growth curve of WT M. ulcerans and MU 1615::Tn84 in 
M7H9 broth. Growth was determined by diluting and plating the 
culture on M7HlO agar plates every 5 d for a duration of 15 wk. 
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secrete a protein toxin which caused necrosis but results from these studies were
complicated by the fact the protein fractions were contaminated with
mycolactone (65). In order to investigate the concentration-dependent activity of
mycolactone more thoroughly, fibroblasts were exposed to increasing concentrations of
mycolactone (15 ng - 15 J.A.g/ml) and assayed for necrosis as measured by LDH release,
and apoptosis. At both 4 and 24 h, 15 J.A.g/ml mycolactone caused pronounced LDH
release whereas other concentrations of mycolactone had little effect (Fig. 3.7). By 24 h
post-treatment, mycolactone at 15 ng/ml and 150 ng/ml caused significant apoptosis (Fig.
3.8). Microscopic observation of cells at 4 h treated with high concentrations of
mycolactone showed the presence of many swollen cells, consistent with death via
necrosis (data not shown). Swollen cells were not seen at low concentrations of
mycolactone though clear cytoplasm and eccentric, shrunken nuclei were common. These
results showed that effects of mycolactone were concentration dependent and included
both rapid changes in cell permeability, as measured by LDH release, and apoptosis.
M. ulcerans is defective in neutrophil chemotaxis
The relative paucity of neutrophils in human and guinea pig M ulcerans lesions
compared with M marinum lesions could be due to a defect in neutrophil recruitment
and/or because neutrophils that are attracted to the site of infection are rapidly killed. To
explore the possibility of a defect in neutrophil chemotaxis, M ulcerans 1615, and MU
1615::TnI19, were tested for their ability to recruit human neutrophils in an in vitro
chemotaxis assay. Neither WT M ulcerans nor MU 1615::TnI19 induced a chemotactic
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Fig. 3.7. Mycolactone-mediated necrosis ofL929 murine fibroblasts. 
Cytotoxicity measured by LDH release. Culture supernatants were collected 
from wells containing L929 cells 4 and 24 h after mycolactone treatment, and 
the amount ofLDH was measured using a CytoTox 96 assay kit (promega). 15 
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Fig. 3.8. Mycolactone-mediated apoptosis ofL929 murine fibroblasts. 
Apoptosis was assessed with the cell death detection enzyme-linked 
immunosorbent assay (ELISA) kit and expressed as fold enrichment of 
nucleosomes. Data are mean and standard deviation of the values 
obtained from triplicate samples. 15ng, 150ng versus all other treatments, 
p < 0.005. 
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response in human neutrophils (Fig. 3.9). In contrast, M marinum, a mycobacterial
control, elicited as great a chemotactic response as the positive IL-8 control (data not
shown). Conclusions regarding the differential ability ofM marinum compared with M
ulcerans to recruit neutrophils cannot be drawn from these studies since there are
numerous genetic differences between these species aside from the difference in
mycolactone.
Mycolactone results in rapid necrosis of neutrophils
A second explanation for the relative lack ofneutrophils in M ulcerans lesions
could be that neutrophils recruited to the site of infection are killed. Because neutrophils
are short-lived cells with a high rate of spontaneous apoptotic cell death, it was only
possible to determine the potential ofmycolactone to cause neutrophil death via necrosis.
Results from these studies show that mycolactone causes dose-dependent necrosis of
human neutrophils within 24 h (Fig. 3.10 A, B). Neutrophils treated with high
concentrations of mycolactone showed severe loss of membrane permeability as shown
by cytotoxic effects seen in Fig. 3.11. Taken together, these results suggest that the
paucity of neutrophils in M ulcerans infection focus may be due to a lack of chemotactic
stimuli as well as to killing of cells which are attracted to the site of infection.
Discussion
M ulcerans is unique among mycobacterial pathogens in three respects: 1) the
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Fig. 3.9. Migration of human neutrophils in response to wild and mutant 
strains of M ulcerans or purified mycolactone. Chemotaxis assays were 
performed using a double-chamber system. Wild and mycolactone mutant 
strains of M ulcerans were used as chemoattractants in the lower chamber 
and human neutrophils purified from peripheral blood were seeded in the 
upper chamber. lnterleukin 8 (lL-8) (100nM) served as positive control and 
buffer alone as a negative control. After 1 h transmigrated cells were 
recovered from the lower chamber and counted using a hemocytometer. Data 
are expressed as chemotactic index (ratio of chemotactic movement to 
random migration) ±standard deviation. lL-8 versus WT M ulcerans 1615 















LDH release by human neutrophils after 4 h 
tJ 
myc 4ng myc 111ng myc 1ug myc S.3ug 
LDH release by human neutrophils after 24 h ~ 













Fig. 3.10. Necrosis of human neutrophils treated with different concentrations 
of my col act one for 4 (A) and 24 (B) h. Values obtained were normalized by 
subtraction of background levels of necrosis of untreated cells at each time 
point. All experiments were performed in triplicate. Data are means ± standard 
deviations (n=3) from one representative experiment of two. Highest 
concentration (5.3 !-lg, 1 !-lg) versus all other treatments, P :::; 0.005. 
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Fig. 3.11. Cytotoxic effect of mycolactone on human neutrophils. 
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ofM ulcerans infection. The intracellular survival of M ulcerans mycolactone mutants
in vivo was a surprising finding as the failure ofMU myc- to produce an ulcer in an
earlier study by George et al. (36) had led to the assumption that the organisms would be
cleared.
An interesting implication from these findings is that if mycolactone production
was turned off during infection, M ulcerans like other pathogenic Mycobacteria species
might persist within macrophages. This conclusion is also supported by in vitro
macrophage studies. The finding that mycolactone causes a rapid change in cell
permeability resulting in necrosis at high concentrations is a newly reported phenotype.
What is the biological relevance of these findings? In a 4 week stationary culture, M
ulcerans produces 4 - 6 I-tg/ml mycolactone of which 75% (3 - 4.5 I-tg) is cell associated
(75). By extrapolation from in vitro growth production, it is estimated that injection of
107 M ulcerans introduces 0.3 - 0.45 Ilg mycolactone into the dermis. Mycobacteria are
nonmotile. In the absence of inflammatory cells, localized replication of mycobacteria
leads to formation of micro-colonies which could result in extremely high local
mycolactone concentrations. Analysis of the bacterial load in human tissue by
quantitative peR suggests that an infection focus contain greater 109 organisms (76). If
mycolactone production in vitro accurately reflects production in vivo, mycolactone
concentration used in our studies is well within the range likely to be present in natural
infections. This suggests that both necrosis and apoptosis are relevant mycolactone
effects.
Based on these studies the following role for mycolactone in the virulence ofM
ulcerans is proposed. As organism replicates and mycolactone is secreted, a toxin
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gradient fOTIns. The death of adipocytes leads to release of fatty acids which creates a
hydrophobic environment facilitating diffusion ofmycolactone. Inflammatory cells are
killed rapidly when they encounter high concentrations of mycolactone and cannot
disperse bacteria. Inflammatory cells more distant from the necrotic center are killed via
apoptosis. This sequence of events creates and maintains locally high mycolactone
concentrations which results in death of inflammatory cells, and prevents amplification of
the initial immune response. Unfortunately, the route of transmission, the infective dose
of M ulcerans, the regulation of toxin production in vivo, the amount of mycolactone in a
human lesion and the stability of the molecule in vivo are unknown. Studies with MU
myc- suggest that if mycolactone production was turned offat some point in infection, M
ulcerans might indeed have an intracellular phase. This is consistent with the finding that
M ulcerans patients mount a Thl immune response to infection leading to the widely
held conviction that M ulcerans has an intracellular phase which has not been detected
(7, 52, 56, 77).
In vivo, the relative paucity of neutrophils in M ulcerans infection as well as the
differential neutrophilic response to WT M ulcerans and MU myc- suggest that
mycolactone might have an effect on neutrophil recruitment. However, results from our
in vitro studies with human neutrophils suggest that whereas M ulcerans promotes little
chemotaxis, this is not likely to be due to the presence of mycolactone. The
immunomodulatory effects of mycolactone are not surprising considering that many
antibiotic macrolides such as erythromycin have anti-inflammatory properties (37).
In the case of pathogenic mycobacteria such as M tuberculosis, M bovis and M
leprae, phagocytic uptake has been shown to occur by binding to receptors on the plasma
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membrane of phagocytic cells. These receptors include complement receptors (CRl,
CR3, CR4), for opsonized and non-opsonized entry, mannose receptors (MR) that bind
mannosylated structures on the bacterial surface, Fcy receptors that internalize IgG-
opsonized bacteria and scavenger receptors (43, 48,51, 78). In addition to binding one or
more receptor molecules, M tuberculosis has been shown to interact with the plasma
membrane sterol cholesterol. It has been hypothesized that the extremely glycolipid-rich
mycobacterial cell wall may contain components that interact directly with cholesterol
(78, 79).
Toll-like receptors are also involved in cellular recognition of mycobacteria (51).
TLR2, TLR4 and, more recently, TLRl/TLR6 that heterodimerize with TLR2, have been
implicated in the recognition of mycobacterial antigens. The mycobacterial cell wall is
composed of different glycolipids such as lipoarabinomannan (LAM-AraLAM,
ManLAM, PILAM), mycolic acid, lipopeptides, and phosphoinositol. PILAMs are
usually considered as pro-inflammatory molecules while ManLAMs are anti-
inflammatory molecules. TLR-2 mediated cell activation has been described for LAM,
LM (lipomannan), phosphatidyl-myo-inositol mannoside (pIM), and the 19-kDa
mycobacterial lipoprotein which is a potent inducer ofT-cell responses. It is thought that
a balance between PIM, LM and LAM synthesis by pathogenic mycobacteria might
provide pro- or anti-inflammatory immunomodulatory signals during infection (80,81).
From several lines of evidence, it has become clear that phagocytosis does not lead to
immune activation in the absence of functional TLRs (51). Comparatively, little is known
regarding the cell wall ofM ulcerans and its interaction with host cells. Detennination of
all the cell wall components ofM ulcerans and comparison with that of other
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intracellular pathogenic mycobacteria may help in understanding what role the cell wall
plays in the difference in initial recognition and interaction with resident immune cells,
phagocytosis and further amplification of the immune response.
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Chapter 4
CYTOKINE AND CELL-ADHESION MOLECULE RESPONSE TO
MYCOBACTERIUM ULCERANS
Introduction
M ulceranr infection is characterized pathologically by a predominance of
extracellular bacteria, massive necrosis, little acute or chronic inflammation in the lesion
and a paucity of mononuclear cell inflammatory response (2, 46, 49). Tissue necrosis has
been attributed to mycolactone, the toxin produced by M ulcerans (36). After infection, a
critical role played by the innate immune system is to emit' alarm signals' that warn of
pathogens in the vicinity. These signals (cytokine, chemokine, adhesion molecule
responses) result in rapid recruitment and activation of antigen presenting cells, which are
critical early events in launching a productive immune response (82). Virtually all
pathogenic mycobacteria except M ulcerans produce granulomas in their vertebrate
hosts. Granuloma formation typically starts from aggregates of mononuclear phagocytes
surrounding individual infected macrophages and include giant cells and T cells (43).
Production of inflammatory mediators by infected phagocytes, such as TNF-a, has been
shown to be an essential requirement to initiate timely chemokine-induced cell
recruitment during infection with M tuberculosis (83).
Information regarding the pro-inflammatory cytokine, chemokine and cellular
adhesion molecule response to M ulcerans is limited. Table 2 includes a list of cytokine
responses to M ulcerans in vitro and ex vivo that have been studied to date. Previous
studies have shown that a high density lipid fraction from M ulcerans culture filtrate
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Table 2. Cytokine response to M uicerans.
Cytokine Cells used Stimulant Response Reference
Response
Interleukin-2 HumanT High density lipid Inhibited Pahlevan et
lymphocytes fraction from M ai., 1999
(T cell line uicerans culture
3895, Jurkat filtrate
T cells)
Tumor necrosis Human High density lipid Inhibited Pahlevan et
factor-alpha PBMC from fraction from M ai., 1999
healthy uicerans culture
subjects filtrate
Interleukin-10 Human High density lipid Inhibited Pahlevan et
PBMC from fraction from M ai., 1999
healthy uicerans culture
subjects filtrate
Interferon- Human PPD Inhibited Westenbrink



















Interleukin-4, 5, Human Live M uicerans, Increased Gooding et




inhibits IL-2 production of activated lymphocytes, and TNF-a expression ofLPS-
stimulated monocytes. Immunomodulatory effects ofM u/cerans and purified
mycolactone toxin on TNF-cx production, secretion of IL-8, an important neutrophil
chemotactic factor and cell-adhesion molecules have not been addressed so far.
Important effector mechanisms of host defense include secretion of chemokines
and cytokines (83-86). Regulation of these host effector mechanisms depends on
pathways initiated by ligand-receptor interactions on the surface of cells in the area of
infection. Central roles in these intracellular pathways have been assigned to the nuclear
factor kappa B (NF-KB) system and to mitogen-activated protein kinase (MAPK)
pathways, such as the extracellular signal-regulated kinase (ERK), c-JUN NH2-terminal
kinase (JNK) and p38. Disruption of these pathways leads to impaired secretion of
antibacterial effectors like TNF-a, IL-I, and IL-8 (87) (88,89).
Early inflammatory responses are essential for generating antigen-specific
effector cells of adaptive immunity. Primary cells that produce TNF-a are monocytes and
macrophages (90). Cytokines produced immediately after infection orchestrate the next
wave of the innate immune response, cell recruitment and activation (68). Protective
innate immunity against mycobacteria depends on TNF-a and IL-12 production to
regulate the activation of T-lymphocytes and to stimulate the antimycobacterial capacity
of infected macrophages (84). Polymorphonuclear granulocytes (PNG) are the first cells
which, in response to microbial invasion, migrate from the blood into tissue sites, where
they participate in the early inflammatory response. Chemokines like IL-8 are potent
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leukocyte attractants. IL-8 is expressed by macrophages and PNG upon appropriate
stimulation. Receptors for IL-8 have been identified on PNG and natural killer (NK)
cells. IL-8 has many biological activities including induction of chemotaxis, exocytosis,
respiratory burst, and up regulation of complement receptors 1 and 3 (85).
The NF-KB family of transcription factors is a group of evolutionarily conserved
proteins which are important in regulation ofthe immune system. These transcription
factors are involved in the development ofaccessory cell and lymphocyte populations
and expression ofnumerous proteins involved in innate and adaptive immunity. Invasion
of a host by a pathogen is frequently associated with activation ofNF-KB, which
coordinates various aspects of immune function required for resistance to infection (91).
NF-nB activation can be inhibited by blocking various points in the NF-nB/InB pathway.
Interfering with degradation ofI-KB is a strategy commonly employed by some
pathogens to inhibit activation ofNF-KB (86).
Adhesion molecules expressed on immunocompetent cells play important roles in
cellular interactions for the development of immunological responses. Intercellular
adhesion molecule-l (ICAM-l) plays a role in lymphocyte trafficking by allowing
ICAM-l bearing endothelial cells to interact with leukocyte function-associated antigen-l
(LFA-I) on lymphocytes, and thereby facilitate migration of lymphocytes to sites of
inflammation along endothelial cells (92,93). Moreover, the interaction ofLFA-l with
ICAM-l is critical for effective cellular interactions ofT cells with antigen presenting
cells, including macrophages, and the consequent activation of resting T cells. ICAM-l
augments T-cell proliferation and is pivotal in recall antigen responses of T cells to
purified protein derivative ofM tuberculosis (93). A recent study by Lopez Ramirez et
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al. (94) showed that ICAM-1 expression on THP-1 human monocyte- derived cell line
was potently increased by stimulation with M tuberculosis. In addition, the in vivo study
by Sullivan et al. (95) concerning M leprae infection revealed that granulomas from
tuberculoid leprosy displayed ICAM-1 expression. This implies that ICAM-1 plays
important roles in enhancing the immune and inflammatory responses to mycobacteria
(96). Therefore, it is of interest to know the profiles of ICAM-1 expression by
macrophages after stimulation with M ulcerans.
This study demonstrates that M ulcerans and mycolactone do not induce TNF-a
and IL-8 production by macrophages at the protein level. IK-B degradation is not affected
by mycolactone. Decreased expression of cell-adhesion molecules like ICAM-1 may
contribute to poor inflammatory response-lack of cellular interactions which prevents
release of inflammatory cytokines as well as the influx of macrophages and neutrophils
seen in Buruli ulcer lesions.
Results
TNF-a secretion by THPI cells in response to wild and mycolactone mutant strains
ofM. ulcerans
Levels ofTNF-a produced by THP-1 cells following infection withM ulcerans,
mycolactone mutant strain of M ulcerans or mycolactone are shown in Fig. 4.1. In
response to infection with WT M ulcerans or mycolactone, very low levels of TNF-a
(almost equivalent to background levels ofTNF-a secreted by control untreated cells)
















Fig. 4.1. TNF-a production by differentiated THP-l cells. Cells were treated 
with wild type M ulcerans (1615), a mycolactone mutant ofM ulcerans 
(MU 1615A), mycolactone (400 ng/ml), LPS (10 ng/ml) or wild type M 
ulcerans and LPS (10 ng/ml). Untreated cells served as controls. 
Supernatants were harvested 24 h post infection and secreted TNF - a levels 




significant levels ofTNF-a. Interestingly, WT MU 1615 inhibited LPS induced TNF-a
release by THP-l cells.
IL-8 secretion by THP-l cells following infection with M. ulcerans strains
Differentiated human monocytes (THP-l cells) were treated with WT M
ulcerans, myc- M ulcerans (119), M marinum, M fortuitum, or mycolactone for 24 h.
Culture supernatants were collected, and IL-8 concentrations were determined by ELISA.
The levels of IL-8 produced by THP-l cells following infection with WT M ulcerans or
myc- M ulcerans are shown in Fig. 4.2. WT M ulcerans, myc- M ulcerans or
mycolactone fail to stimulate IL-8 secretion beyond baseline level secreted by untreated
control cells. In contrast, other pathogenic mycobacteria like M marinum and M
fortuitum stimulate IL-8 production. LPS treatment also stimulated IL-8 production (data
not shown).
Macrophage surface expression ofICAM-l following infection with M. ulcerans or
treatment with mycolactone
In this the level of macrophage surface expression ofICAM-l, a key protein known to
playa major role in cell-cell adhesion was also examined. As shown in Fig. 4.3, flow
cytometric analysis revealed an increase in ICAM-l-positive macrophages in WT M
ulcerans infected cells relative to uninfected cells at 24 h. However, infection of cells
















Fig. 4.2. IL-8 production by differentiated THP-1 cells. Cells were treated 
with wild type M ulcerans (1615), a mycolactone mutant of M ulcerans 
(MU 1615::Tnl19), mycolactone (500 ng/ml), M marinum or M fortuitum. 
Untreated and ethanol treated cells served as controls. Supernatants were 
harvested 24hrs post infection and secreted IL-8 levels were determined by 
































Fig. 4.3. Flow cytometry analysis of ICAM-1 expression by THP-1 cells. (A) in 
response to 24 h infection with WT MU1615 (blue line), myc- MU 1615::Tn119 
(yellow line), LPS (brown-100ng or green-lOng line) or control cells (purple line). 
(B) ICAM-1 expression by THP-1 cells in response to 24 h treatment with 
mycolactone (100 ng/mI, fluorescent green line, 1000 ng/mI, orange line), LPS 
(10 ng/ml, dark green line, lOOng, pink .line) or mycolactone (1000 ng/mI, blue 
line, 100 ng/mI, red line) and LPS (10 nglml) or control cells (purple line). 
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in expression of ICAM-1 as did LPS treated cells. There was an increase in the number
ofICAM-1 positive cells in mycolactone treated samples when compared to untreated
cells. Surprisingly, mycolactone (100 ng as well as 1000 ng) caused a shift in the peak of
ICAM-1 positive cells suggesting a decrease in LPS mediated expression ofICAM-l.
This dampening of ICAM-1 levels provides a possible mechanism for the poor
infiltration of inflammatory cells in a Buruli ulcer human lesion. These results suggest
that mycolactone may play an important role as a modulator of ICAM-1 expression.
Effect of mycolactone on LPg mediated degradation of I-KBa
Many genes that are implicated in the initiation of immune, acute phase, and
inflammatory responses are regulated at the level of transcription ofNF-KB (97) (89).1-
KBa is a potent inhibitor ofNF-KB, and degradation ofI-KBa via the ubiquitin pathway
is necessary for NF-KB activation, nuclear translocation and subsequent transcriptional
activation of immune response genes (88). Therefore, the effect of mycolactone on
degradation ofl-KBa was examined. Cellular extracts from J774 cells treated with
mycolactonelLPS were analyzed for 1-KBa degradation by western blotting with an anti-
I-KBa polyclonal antibody. As shown in Fig. 4.4, treatment with LPS led to the rapid
disappearance of the immunoreactive I-KBa band within 15 min; this band returned to
basal levels within 30 min. LPg induced degradation ofI-KBa was not inhibited by
myco1actone at the concentration tested. Taken together, these results suggest that the
molecular target for mycolactone may not be dissociation ofNF-KB from I-KB and







Fig. 4.4. (A) Cornmassie stain of proteins from 1774 cell extract (B) 
Western blot analysis ofIkBa degradation in 1774 cell line. Lanes: 1, 
protein standard markers; 2, control; 3, LPS 20 ng/ml 15 min; 3, LPS 
20 ng/ml 30 min; 4, mycolactone 100 ng/ml 1 h; 5, mycolactone 100 





Monocytes/macrophages and TNF-a are key elements in anti-mycobacterial
responses (28). The importance ofNF-KB in the transcription of a number of
proinflammatory genes makes this transcription factor key to the immune inflammatory
response (98). Data from this study using whole bacterial cells of WT M ulcerans, myc-
M ulcerans and purified mycolactone confirms studies published by Pahlevan et al. (28)
showing the inhibitory effect of high density lipid (HDL) fraction extracted from culture
filtrate of M ulcerans (Strain 7634) on TNF-a production by RAW 264.7 murine
macrophage cell line. Interestingly, the same group showed that TNF-a-induced
activation ofNF-KB was inhibited by the HDL fraction of WT M ulcerans. This study
shows that mycolactone does not inhibit LPS induced I-KBa degradation in 1774 mouse
macrophages. Recent studies by Desaki et al. (88) showed similar results in human
bronchial epithelial cells with another macrolide erythromycin. Erythromycin did not
inhibit degradation ofI-KBa or NF-KB DNA-binding activity. Interestingly,
erythromycin suppressed activation ofNF-KB and production ofIL-8 (88).
It is possible that mycolactone may act on the signaling pathway via a different
downstream target. It is known that IL-8 is expressed in response to LPS, TNF-a and
aggregated immune complexes (99). The inability of M ulcerans to stimulate TNF-a
production and the possible inability to form immune complexes due to the presence of
large clumps/masses of extracellular bacteria may explain the inability of cells to secrete
IL-8.
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Lymphocyte adhesion is a necessary event for cell to cell interactions required to
produce an immune response (92). Recently, it was found that stimulation ofTHP1 cells
with M tuberculosis or its lipoarabinomannan elicited an increase in ICAM-1 expression
(93, 94). In addition, in cases of tuberculoid leprosy lesions characterized by strong
delayed-type hypersensitivity (DTH) against M leprae, keratinocytes exhibited
pronounced ICAM-1 expression. Conversely, in lepromatous leprosy patients who show
a serious defect in DTH, keratinocytes ICAM-l expression was low (95, 100). Another
study showed that infection of murine peritoneal macrophages with M avium lead to an
increase in ICAM-1 expression (101). In the present study macrophage ICAM-1
expression is decreased by WT M ulcerans and mycolactone in comparison to the
mycolactone mutant MU1615: :Tnl19 stimulated cells. In addition, LPS induced
expression of ICAM-1 is also decreased by mycolactone. Decreased expression of
ICAM-1 on cells in the area of lesion may playa role in the immune response seen in
Buruli ulcer patients. It would be interesting to see if there is a difference in expression of
ICAM-1 and other cell adhesion molecules in skin samples from Buruli patients with
early, ulcerative and healed lesions.
A number of studies have shown the inhibitory effect of macrolides on
inflammatory immune responses (37-39, 88, 99). Data from studies in vitro and in animal
models support the inhibitory effects of macrolides on neutrophil influx and chemotactic
activity (37, 99). Long-term treatment with macrolide antibiotics has been shown to
decrease levels ofIL-8 in the bronchial alveolar lavage (BAL) fluid of patients with
diffuse parabronchiolitis, and to decrease concentrations of IL-8 released by eosinophils
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from atopic subjects. Cultured human bronchial epithelial cells treated with erythromycin
showed reduced levels ofIL-6, IL-8 and ICAM-I (88).
Results from the present study suggest that M ulcerans and mycolactone inhibit
pro-inflammatory cytokine response and decreased ICAM-l expression which may
contribute to the paucity of inflammatory cells seen in the area of infection. Further
studies to understand how mycolactone may either disrupt or redirect signaling pathways
that lead to immense tissue damage and a lack of immune response may help in






MICROARRAY ANALYSIS TO INVESTIGATE
MODE OF ACTION OF MYCOLACTONE
Introduction
The unique pathology seen in Buruli ulcer is attributed to mycolactone (13, 36,
40, 102). Its mode of action is unclear, however, in a guinea pig model of the disease,
purified mycolactone injected subcutaneously reproduces the natural pathology, and
mycolactone-negative variants were avirulent, implying a key role for the toxin in
pathogenesis. Mycolactone was also shown to have cytotoxic, anti-inflammatory and
immunosuppressive properties (36). On cultured fibroblasts and macrophage cell lines,
mycolactone induced cell rounding, inhibited protein synthesis, arrested cells in GO/G1
stage, and eventually cell death (13,35,36). In vitro experiments showed that the major
mycolactones, a mixture of cis-trans isomers (mycolactone A and B), produced apoptosis
and necrosis in many human cell types (13, 65, 103). Mycolactone has also been shown
to induce cell-cycle arrest in cultured lymphocytes, followed by apoptotic cell death (28).
There is a general inhibition for protein synthesis in vitro in response to mycolactone
(35). It has been postulated that local secretion of mycolactone reduced the cutaneous
inflammatory response and may contribute to the development of the Buruli ulcer (40).
However, it is still not clear if mycolactone causes global immunosuppression in the host.
The mode of action of mycolactone is still unknown. Studies using a biologically
active fluorescent mycolactone derivative, bodipy mycolactone, have suggested that
mycolactone enters cells by diffusion and accumulates in the cytosol (41). The same
researchers showed that uptake of mycolactone is both nonsaturable and noncompetitive
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with excess mycolactone, consistent with passive diffusion of this toxin through the cell
membrane. These facts, combined with the inability of signal transduction inhibitors to
inhibit mycolactone cytopathicity point towards the presence of a cytosolic target for
mycolactone (41). The molecular mechanismls underlying the cytotoxic effect caused by
mycolactone have not yet been uncovered in detail. In view of the complex factors that
may contribute to mycolactone activity, gene expression profiling may make it possible
to identify various genes involved in mycolactone-mediated cytotoxicity.
In the last few years, microarray technology has emerged as the method of choice
for large-scale gene expression studies. It provides a rapid and efficient method to
investigate the entire transcriptome ofa cell (104-108). Microarrays have become an
important tool for analyzing genomic transcriptional programs in diverse biological
processes. Microarray analyses are utilized in a variety of research areas such as
investigation of gene networks in physiological pathways, analysis of genetic variation,
host-pathogen interactions or for studying host gene expression programs modulated by
different drugs and to identify the pathway of action of the compounds new therapeutic
drug targets. The term toxicogenomics describes another exciting field of microarray
application, which offers the possibility to characterize transcriptional responses towards
toxic compounds (109-110). Toxicogenomic approaches comprise the assessment of gene
expression profiles of animal tissues or cell cultures after administration of toxicants,
which may lead to the establishment of toxicant-specific "fingerprints." Another
challenge provided by toxicogenomic-based investigations is the possibility to assess the
toxic mode ofaction of a compound. Interpretation of transcriptional alterations and
assignment of differentially expressed genes to biological pathways might culminate in
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the generation of hypotheses about toxicological mechanisms of compounds (111). The
simplest way to identify genes ofpotential interest through several related experiments is
to search for those that are consistently either up- or downregulated (112). The principle
of a microarray experiment is that mRNA from a given cell line or tissue is used to
generate a labelled sample, sometimes termed the 'target', which is hybridized in parallel
to a large number of DNA sequences, immobilized on a solid surface in an ordered array
(Fig. 5.1). Using this method, tens of thousands of transcript species can be detected and
quantified simultaneously (113).
In this study, microarray technology was used to gain a global and molecular view
of cellular transcriptional responses to mycolactone and to identify important genes
modulated by the toxin. To investigate cellular responses to mycolactone, changes in
gene expression caused by treatment of human monocytes with different concentrations
of mycolactone were analyzed using DNA microarrays. Analysis of genes induced by
mycolactone revealed up-regulation and down-regulation of several interesting genes.
Here the significance of modulation of some of these genes by mycolactone in M
ulcerans pathogenicity, mycolactone-mediated cytotoxicity and disease outcome is
discussed.
RNA preparation and microarray analysis
THP-1 human monocyte cells were plated at 5x105 cells/ml in 35mm tissue culture flasks
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Fig. 5.1. Schematic overview of probe array and target preparation for spotted cDNA 
microarrays. Array preparation: inserts from cDNA collections or libraries (such as 
IMAGE libraries) are amplified using either vector-specific or gene-specific primers. 
(Taken from Schulze, A., et aI., 2001). 
76 

supernatant was removed and fresh tissue culture medium supplemented with 10% FCS
and L-glutamine was added. Cells were treated with two different concentrations of
mycolactone (15 ng/mlor 100 ng/ml) for 0.5.2 or 8 h. Control cells were treated with an
equal volume of ethanol. Total RNA was isolated at the indicated time points from
mycolactone-treated and control macrophages using Trizol™ (Invitrogen. Carlsbad. CA)
according to manufacturer's instructions. Total RNA was further purified using the
Rneasy kit (Qiagen, Valenda, CA). Quality and quantity of RNA was assessed by
measuring the A260/A280 ratio and by analysis on ethidium bromide stained 1% agar
gels.
Probe synthesis and DNA microarray hybridization were performed by Drs. Anne
Mueller and Karen Guillemin in Dr. Stanley Falkow's laboratory at Stanford University
School of Medicine. Detailed protocols for RNA labeling and hybridization can be found
at http://cmgm.stanford.edu/pbrown/protocols/index.html.Briefly, total RNA was used
for single stranded cDNA probe synthesis incorporating aminoallyl-dUTP, which was
subsequently coupled with Cy3 (for the control sample) or Cy5 (for the experimental
sample). The fluorescently labeled experimental and control samples were combined and
hybridized to a 40,000-element human cDNA microarray.
Arrays were scanned using a GenePix 4000A scanner and images were analyzed
with GENEPIX PRO software (Axon Instruments, Foster City, CA). Data were filtered
by omission of spots, with regression correlations < 0.6, and by selection of genes whose
logz of red:green normalized ratio was > 2 (i.e.• normalized ratio is more than two
standard deviations away from mean). Only genes with > 70% good data for all arrays
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were included for log2 transformation and analysis. These criteria were met by 1596
genes. Data were then filtered so that the absolute values of the fold change between
experimental and reference sample was C!: 4. Annotations about individual genes were
obtained from the National Center for Biotechnology Information (NCBI)
(http://www.ncbi.nlm.nih.goc) and SOURCE (http://genome-www5.stanford.edu/cgi-
bin/SMD/source/sourceSearch) websites.
Results
Data were used to identify genes that might be critical in the cytotoxic effects
caused by mycolactone. To identify transcriptional events regulated by mycolactone, data
obtained from THP-l cells treated with two different concentrations (low-IS ng/ml, high-
100 ng/ml) ofmycolactone for 0.5 (early), 2 (intermediate) and 8 (late) h were compared.
Raw microarray data (shown in appendix figures A 1.1- A 1.4) represent genes whose
absolute values of the fold change between experimental and reference sample was C!: 4 in
at least two sets of microarray experiments for each condition. Genes that were
significantly up-regulated included those related to transcriptional repressors, cytoskeletal
rearrangement, cell cycle control/proliferation, apoptosis, G-protein receptors, tumor
supression and immune response. Genes down-regulated throughout the time course
included those related to DNA repair, inactivation of complement and metalloproteinases,




Genes up-regulated by mycolactone treatment
Treatment ofTHP-l cells with mycolactone for 0.5 h (Table 3) caused an increase
in expression of genes related to transcription (TLE4, DSCRlLl, RING1, several zinc
finger proteins), immune response (HLA-DPBl, DEFA4, CCL7, ITIH4, CD28, STAT4),
sulfotransferase enzymes (involved in modification of drugs, hormones, xenobiotic
compounds), carbohydrate metabolism (PFKP-key control step of glycolysis),
apolipoprotein receptor (LRP8), transmembrane signaling (PLCG2), tumor suppressors
(LLGL1), calcium transport (pLN- regulates activaty of calcium pump) and apoptosis
(CASP3).
Mycolactone treatment for 2 h (Table 4) resulted in an induction of genes related
to transcriptional repressors/inhibitors/regulators (SIRT4, T, HOXB2, FLJ36991), cell
cycle and maintenance (PKYMTl, AK2), immune response (ILlR2, AZUl, COLEClO),
fatty acid, steroid metabolism (RODH, CYPllBl, RGRX), receptors (GPR105,
AVPRlA, PTGER3, ROR2, GC, OXTR), signaling (PRKCM), tumor (BAIl, TSSCl,
PRKCG, KLK6) and voltage activated potassium channel (KCNH2). Genes modulated
by 8 h (Table 5) treatment of mycolactone are related to apoptosis (BAX), immune
response (CD86, FREB), cytochrome P450 (CYP2Sl), transport/trafficking (STARD4,
DDHDl, SLC27A4, ARFGAPl, APP) and pH regulation (SCL9A2).
Genes down-regulated by mycolactone treatment
Genes down-regulated throughout the time course (0.5, 2 and 8 h) as shown in
Table 6 were those related to transcription (JUN, MATR3, POGZ), cell cycle control
79





























































































Negative regulator of cell cycle (mitosis)
Apoptosis, Cell maintenance
Cell differentiation, proliferation
Acts on G proteins (Rho,Rapl,Ki-Ras)
Dynein mediated microtubule sliding inactivates PAF
Receptor for <Pj..t stimulating factor
Receptor (endocytosis of glycoproteins by <Pj..t)
Decoy receptor of IL 1










G-protein receptor (prostaglandin E2)
Receptor protein tyrosine kinase




Angiotensin catalyzing enzyme (bradylinin inhibitor)































Cytoskeletal remodelling, signal transduction
Inhibit cell migration, ligand for integrins
Mediate phagocytosis of IgG coated pathogens
Immune response, acute phase reactions
Cyt p450
UDP-glucose dehydrogenase






Proton extruding system (pH balance)
DNA-dependent RNA polymerase






































Repress transcriptional elongation by RNA pol II
Transcription regulator
Transcriptional regulator of adaptive response to hypoxia
Transcription regulator




Inhibits signal transduction (B cell proliferation regulation)
Immunity to opportunistic infection
Production ofleukotrienes
Antioxidant enzyme



















(PPP2RIB, RCL, CDK2API, MAGEDI), cytoskeletal rearrangement (MACFI,
CAPZAI), inflammation (FCGRT, SCYEl, ITGAI, PRDX4, LTC4), immune response
(lL6R, FCERIG, RGSI, PTMA), signal transduction (SPRY2, RANBP7, ARHA,
YWHAZ), tissue repair/damage (MCP, TIMP2) and DNA repair (RAD23B)
Discussion
Taken together, the array data provided for the fIrst time a global view of
mycolactone-mediated signal transduction in host cells at the molecular level. The
cytotoxic response to mycolactone involved several genes modulated signifIcantly and
consistently. The most striking changes were in genes required for cell cycle progress
and transcription factors (regulators, repressors). Others included genes related to cell
cycle arrest, apoptosis, tumor suppression and immune response. Additionally, several
signal-transduction, cell growth/division, transcription regulation and inflammation
related genes that were signifIcantly down-regulated in mycolactone treated macrophages
were identifIed. Data from this study provide new insight into the host gene-expression
pathways induced by mycolactone.
Pimsler et aZ. (49) showed that a crude culture fIltrate of M uZcerans inhibited T
cell activation. Another group, Pahlevan et aZ. (28) also showed that a high density lipid
fraction of M uZcerans inhibited T cell activation. The same group also showed that the
factor abrogated TNF-induced NF-KB activation but did not inhibit degradation ofIKBa
induced by TNF, indicating that the target for its activity lies within an undefIned part of





Calcium is used by cells to modulate gene expression programs by various means.
The best known example of calcium regulation through phosphatases is the NF-AT
transcription factor (114, 115). Calcineurin becomes activated on binding calcium and
calmodulin when cytosolic calcium rises, and is inhibited on binding the
immunosuppressants cyclosporin A and FK506 in complexes with their respective
cellular receptors (116).
Calcineurin is a serine/threonine protein phosphatase under the control of
Ca2+/calmodulin and plays a pivotal role in developmental and homeostatic regulation of
a wide variety of cell types (116). It functions as a heterodimer composed of a catalytic A
subunit (CaNA) and a calcium binding regulatory B subunit (CaNB). CaNA displays a
multidomain structure with a catalytic domain at its N-terminus, followed by the binding
regions for the B subunit and calmodulin (CaM). An autoinhibitory domain is located
near the C-terminus, which is thought to be displaced upon CaM binding (117).
The interaction of calcineurin with transcription factors of the NFAT family
following activation of the T cell receptor in leukocytes provides the best characterized
example of how calcineurin regulates gene expression (114, 115, 118, 119). Changes in
intracellular calcium promote binding ofCa2+/calmodulin to the catalytic subunit of
calcineurin (CnA), thereby displacing an autoinhibitory region and allowing access of
protein substrates to the catalytic domain. Dephosphorylation ofNFAT by activated
calcineurin promotes its translocation from the cytoplasm to the nucleus, where NFAT
binds DNA cooperatively with an API heterodimer to activate transcription of genes
encoding cytokines such as IL-2. This basic model ofNFAT activation has been shown
to transduce Ca2+signals via calcineurin in many cell types and to control transcription of
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diverse sets of target genes 'unique to each cellular environment (115). In each case,
NFAT acts cooperatively with other transcription factors that include proteins of the AP1,
cMAF, GATA, or MEF2 families (118). In addition to T cell activation, cellular
responses controlled by calcineurinINFAT signaling include gene transcription factors,
signaling proteins, cell surface receptors, other effector proteins (115, 118).
Down syndrome critical region gene I-like 1 (DSCR1L1), also known as
calcipressin 2/ZAKI4, was identified to be up-regulated early (0.5 h) by microarray
analysis. Previous studies showed that different isoforms ofDSCR1L1 were expressed in
the brain, heart, skeletal muscle, kidney, skin and other organs (120-122). DSCR1L1 is a
feedback inhibitor of calcineurin. It binds to CaNA subunit ofcalcineurin and inhibits its
phosphatase activity, preventing dephosphorylation ofcytosolic NF-AT and its
subsequent nuclear import (117). One possible mechanism by which mycolactone
inhibits the signaling pathway through calcineurinINF-KB activation could be by up-
regulating DSCR1L1, thus preventing translocation ofNFAT to the nucleus.
Further more, down-regulation of transcription factors such as JUN which is a
member of the activator protein-1 (AP-1) complex could inhibit transcription of
downstream immune response gene. Fos and Jun proteins, which are components of the
AP-1 complex of nuclear transcription factors, have been implicated in the regulation of
inflammatory responses (88). This could explain the inhibition of production of several
pro-inflammatory cytokines observed in M ulcerans infection in vitro and in vivo by
several researchers (5, 25, 28, 46,49, 52, 56). It would be interesting to see if expression
ofDSCR1L1 is a direct effect ofmycolactone and to look at the effect of mycolactone on
DNA-binding activity of the AP-1 complex.
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Other macrolides like cyclosporin, FK-506 and rapamycin have similar but
distinct modes of interaction with cyclophilins, calcineurin and transcription factors (116,
119). These immunosuppressive drugs have also been shown to inhibit inflammatory
responses in macrophages (123). FK506 and cyclosporin, when complexed to specific
immunophilins (FK.BPI2 and cyclophilin A, respectively), bind calcineurin at multiple
sites, inhibiting calcineurin activity (114, 115, 124). By inhibiting calcineurin activity,
cyclosporin and FK 506 prevent the nuclear translocation ofNF-AT secondary to
dephosphorylation, thereby suppressing T-cell activation (122) (Fig. 5.2). In a similar
manner, the inhibitory effect of mycolactone on the activation of transcription factors can
playa pivotal role in anti-inflammatory action ofmycolactone.
Up-regulation of several apoptosis related genes like BAX and CASP3 is
consistent with data reported by other groups showing induction of apoptosis in vitro as
well as in vivo (13) (65). Other genes of interest modulated by mycolactone include
LTC4S, ITGAl, TIMP2 and RAD23B. TIMP2, which is an inhibitor of
metalloproteinases (MMPs), was downregulated throughout the time course of the
microarray study. During healthy states, the integrity of the extracellular matrix requires a
correct balance between the amount and activity of matrix-degrading proteolytic enzymes
and their associated inhibitors. It has been demonstrated that MMPs cause tissue
destruction during disease (125). Inhibition ofTIMP2 could contribute to the extensive
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Fig. 5.2. Schematic view of the NFAT activation cycle. NFAT is activated by cell­
surface receptors coupled to Ca2+ mobilization: Immunoreceptors and receptor 
tyrosine kinases (RTKs) activate phosphatidylinositol-specific phospholipase C 
(PLC)y , while G-protein-coupled receptors (GPCR) activate PLCf) . PLC activation 
raises intracellular free Ca2+ levels ([Ca2+ ]1) in several sequential steps. [Ca2+] 
increases result in activation of many calmodulin (CaM)-dependent enzymes, 
including the phosphatase calcineurin and the CaM-dependent kinases CaMKII and 
CaMKIV. Calcineurin dephosphorylates multiple phosphoserines on NFAT, leading 
to its nuclear translocation and activation. Calcineurin activity is inhibited by the 
immunosuppressive drugs cyclosporin A (CsA) and FKS06, which act as complexes 
with their intracellular immunophilin receptors cyclophilin and FKBP12, 
respectively. In parallel, hydrolysis of PIP2 by PLC results in production of 
diacylglycerols (DAG), which activate RasGRP and protein kinase C (PKC). 
Receptor activation is coupled to activation of protein tyrosine kinases (PTKs), Ras, 
MAP kinases (MAPK), and PI-3 kinase (PI3K). MAP kinase activation leads to 
synthesis and activation of Fos and Jun, the components of the heterodimeric 
transcription factor AP-l, which then binds cooperatively with NFAT to composite 
NFAT:AP-l sites found in the regulatory regions of many NFAT target genes. 
(Taken from Hogan, P.G., et al., 2003). 
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Arachidonic acid is a precursor of prostaglandins, leukotrienes (LTs) and related
compounds that have important roles as mediators and regulators of inflammation (126).
Formation of LTC4 by the LTC4 synthase enzyme represents the first committed step in
the synthesis ofLTs (127). LTs participate in a wide array ofpathologic inflammatory,
innate and acquired immune response processes (128). This could be interesting in the
cont~xt of Buruli ulcer where there is minimal inflammation during infection. ITGA1, a
gene that encodes for an intergrin receptor is involved in cell-cell adhesion and plays a
role in inflammation and fibrosis is down-regulated by mycolactone. Another interesting
gene that is down-regulated is RAD23B which is a DNA repair enzyme (109). Further
experiments need to be performed in future to validate expression of the above genes by
real-time PCR, northern or western blot analysis. Expression data described here can be





Buruli ulcer causes great morbidity and is a major health problem in many
tropical countries (133, 134). A single Buruli ulcer, which can cover 15% of a person's
skin surface, contains huge numbers of extracellular bacteria. The infection is
characterized by massive necrosis at the site of infection followed frequently by
debilitating disfiguration. Despite their abundance and extensive tissue damage, there is a
remarkable absence of acute inflammatory response to the bacteria, and lesions are often
painless (4, 71). A major breakthrough in the field came when the toxin made by the
bacteria was identified to be a macrolide named mycolactone and was shown to be
required for virulence (36). The persistence of M ulcerans infection and the
ineffectiveness of antibiotics are thought, at least in part, to relate to a local
immunosuppression caused by the toxin at the site of infection (28, 49). Since the first
documentation of the disease in 1898, not much progress has been made in understanding
the immune response to the bacterium.
One hallmark of most diseases caused by mycobacteria including M tuberculosis,
M bovis, M leprae, M marinum, M haemophilum is the ability of the bacilli to grow
within host cells and cause granulomas. In contrast, M ulcerans primarily forms
extracellular microcolonies within necrotic tissues and is rarely found within host cells
(47). Using a macrophage infection model, the role of mycolactone in the extracellular
location of the bacteria was investigated. Data obtained from the present study showed
that wild type M ulcerans is significantly less efficiently phagocytosed by macrophages
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compared to isogenic mycolactone-negative M ulcerans mutants. Experiments using a
wide panel of myc- M ulcerans strains have shown that presence or absence of
mycolactone determines whether the bacteria are extracellular or intracellular. Exposure
of macrophages to high concentrations ofmycolactone interferes with their phagocytic
ability. These observations that a mycolactone mutant is better phagocytized than the
wild type strain is consistent with the presence of almost exclusively extracellular
bacteria in Buruli ulcer patients. Surprisingly myc- M ulcerans were not cleared by
macrophages and survived within macrophages. Further studies to determine the
intracellular location and compartmentalization of mutants within the macrophage may
yield insight into strategies used by myc- M ulcerans strains for survival within cells.
One of the intriguing findings is that although few WT M ulcerans could be
found inside cells in vitro, intracellular bacteria are rarely found in skin lesions from
patients with clinical disease. This may be a limitation of the in vitro model used which
may not reflect collective events that take place in vivo. Also, the disease is usually
detected in patients at a much later stage where the lesion has already developed. These
patients may be representative ofa scenario where progression to the disease stage is due
to a defect in the immune response leading to unrestricted multiplication of bacteria,
subsequently leading to production of toxin thereby causing tissue damage, necrosis, cell
death and extracellular location of the bacteria.
Though studies showed that uptake of WT M ulcerans is inhibited, specific
events that may lead to this have not been addressed. Recognition ofM ulcerans and
binding by the phagocyte may be affected by mycolactone and other cell wall
components of M ulcerans. Also molecular events involved in internalization of the
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bacteria may be interrupted. It is still not clear whether antiphagocytic activity of
mycolactone is specific or is a more general cytotoxic response with lack of phagocytosis
being a consequence of cytoskeletal disruption and paralysis of the cell. Future studies to
understand the initial events leading to disruption of phagocytosis will help in
understanding the extracellular location ofM ulcerans and the specific effect if any of
mycolactone and other cell wall components of M ulcerans on phagocytic receptors and
uptake. Determining the cell wall constituents of M ulcerans and comparison to that of
other pathogenic intracellular mycobacteria may aid in understanding the contrast in
immune response and cellular location of the bacteria.
TLR activation has been shown to be necessary for innate immunity by inducing
pro-inflammatory cytokines and antimicrobial activity (80, 81). M tuberculosis and its
cell wall components have been show to activate TLR2 and TLR4 pathways leading to an
activation of several signal transduction pathways important in the immune response. In
this context, studying the effect of M ulcerans and mycolactone on TLR signaling may
be relevant. The complement system plays an important role in clearance of bacterial
pathogens by participating in their opsonization through complement deposition
following its activation via the classical or alternative pathways (135). Complement-
opsonized organisms are then recognized by phagocytes through complement receptors
and phagocytosed. Potentially, any pathogen able to interefere with complement
deposition is likely to impair phagocytosis by preventing its recognition as a particle to be
destroyed (61). Pathogenic mycobacteria are known to activate the alternative
complement pathway. Complement activation by M ulcerans has not been studied thus






Experiments studying the effect of mycolactone concentrations on fibroblast cell
lines showed that mycolactone-mediated apoptosis and necrosis was concentration
dependent. Mycolactone caused necrosis at high concentrations and apoptosis at low
concentrations. Chemotaxis assays using human neutrophils showed that neutrophils do
not respond to M u/cerans (WT or myc-) or mycolactone. Mycolactone treatment
resulted in rapid necrosis of human neutrophils in a dose dependent manner in vitro.
These data could be relevant in vivo in human infections where toxin gradients produced
by a pool of extracellular M u/cerans may cause apoptosis or necrosis of inflammatory
cells trying to move into the focus of infection and clear the bacteria.
Lack of an inflammatory reaction during the necrotizing stage of Buruli ulcer
could be due to abrogation of production of inflammatory cytokines (e.g. TNF-a, IL-I,
IFN-y), chemokines (IL-8) and lowered expression of cell-adhesion molecules (e.g.
ICAM-1, selectins, VCAM) which help inflammatory cells reach the site of infection.
TNF-a and IL-8 are key players in immuno-inflammatory responses. Studies regarding
TNF-a response to bacterial infection and mycolactone treatment in vitro showed that
WT M u/cerans and mycolactone did not induce TNF-a production while myc- M
u/cerans did. Interestingly, LPS mediated TNF-a production was inhibited by WT M
u/cerans and mycolactone. Both WT and myc- M u/cerans as well as mycolactone did
not induce IL-8 production. WT M u/cerans and mycolactone induced expression of the
cell adhesion molecule ICAM-l was less than that induced by myc- M u/cerans or LPS.
It will be of interest to look at expression of anti-inflammatory cytokines (IL-4, IL-6, IL-
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10, TGF-(3) and their effect if any, in decreasing the inflammatory response during
infection.
Finally, microarray analysis of genes modulated by mycolactone has yielded
interesting information. Genes that are significantly upregulated by mycolactone included
those related to transcriptional repressors, cytoskeletal rearrangement, cell cycle
control/proliferation, apoptosis, G-protein receptors, tumor supression and immune
response. Genes downregulated by mycolactone included those related to DNA repair,
inactivation of complement and meta1loproteinases, immune response, leukotrienes
production, receptors for collagen and laminin.
To validate the microarray data, real time PCR, northern or western blot analysis
of genes of interest need to be performed. Interest in the calicneurin inhibitor DSCR1L1
resulted from previous research on other macrolide immunosuppressants like FK506 and
rapamycin which are calcineurin inhibitors. It is tempting to speculate that mycolactone
may also act via a similar pathway. Upregulation ofDSCRlLl by mycolactone, if true,
could be very important. Further studies to address the modulation ofDSCRlLl may
yield valuable information regarding the mode of action of mycolactone. Since the major
role of calcineurin is to dephosphory1ate NFAT and regulate the location and activity of
NFAT, the effect of mycolactone on NFAT/calcineurin pathway and subsequent
expression of NFAT dependent genes needs to be studied in detail.
Knowledge obtained from the present study will contribute to a better
understanding of the role of myco1actone in host-pathogen interactions as well as
pathophysiology of the disease and can be expected to have a significant impact on
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181m I ZllF43 II ziIc fialleraroteill 43 (1!l'F'1 II 1Is.14181 II 11113894 II II 1594 
331m II IIIbII Siipieas dlIIl FLJ31803 fis , cloae HT2lU20UlU, IIiIIl sequeace II HI .351m II lU84n3 II II - ~4X<O.,,:'X 1 
Fig. A 1.1. Genes up-regulated 0.5 h post mycolactone treatment. 
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2211'29 II EST. II H::J; . 11':11'''' II H664.06' II II 

110"115" am2 I I interle.:tdn 1 receator . type rr I I Hs:. 25333 I I H ..8386 I I I I ..850 

1051'8.. :aztJ1 I I azuroc:id1n 1. IcaUon::le aJLt:lmI.erobi,a1 urote:i.n 31'\ II Ks.1'2885 I I 0.1'02802 I 

181"88 11 JIioaD .au.i.ens cON». FLJ35'5115 Hs. elon.e TEST:l:2812289 . :IIWt'A seuuenc:e II Ks . 3'J9031 

110060 HIiP.B.I:nerve arowth :foetor . beta uolvuouti.dc II )(S.251151 II T52484 I, HGF-beta-HcJ 

104510 RBPnS II RIflk-b::lndi:h.a' urotein _ne w.t.th mwl-Uu1e ..,1:1.C1nu II Ka.80248 II If''1'200 II 

11'24' :AOP2 II aauaaIIoriA 2 Icol~eet:l.ng cblct) II H8 .31'025 II JU:01'5049 II II 359 

100304 I I I I I I llll6802$0 I I , I 

1060'5 JUOmP20 I I ••RM{ b:lnd:l.nu uroto::l.. 20 I. Ha . 1'0500 II JUl4531'8' II :Prote:1a- t.vro.:1ne k:i 

10....1' ~1115 II Rho uuani.:n.e exch.anae t:actor lGEFl 16 'I Hs . 81'435 II lUl481'50 II I I 2 ' 

103518 :nocn-1 I I ~.ra.n.e-_.oc:1ated. tyros:1ne- and. t.ltreon:i.ne-tlpec.l.Hc cdc:2- :1.nJdbitory J 

11"63 II II II N1'604 II II 

33.'1154 PTPRCllP I I urote:ln tvros:i.ne uho:suJtatase . receutor tYDe . C - assoc:1ated urote:i.n I I 1& 

l.U334 )OQ(10 II IllVOSin . heaVY D01__tide 10 . non-muscl.e II Ha . 2PII5842 II llll4904.... II II 

11616' llVPR:lA II aru:i1rl.ne vasoure••:l.n receutor :lA I I HB.2131 I I JUl44.190 II II ~G2 

10201'4 PRKJiRm II urote:l.n ki.nase . clOfP-denendent . reuu1atorv . tYDO X . beta II Ha.1519 II 

113419 I PTGER.3 II urostau1a:adJ... E ree_tOll:' 3: '.UbtYDe EP3) II Hs.110911' II U406362 II I I 

111"92 • I KCRH2 II uotassi1ll1l vo1taue-CAlted. c~1 . sUb:fam:L1v H leau- re1ated) , JneRber 2 • I ) 

1048'" f I BBS2 II Ba.rd.et- B:1ed1 sVRd.r_ 2 II Ks.332633 II H'31'40 II II 583 

2284'5 I I I I I I I I AA1I53846' I I I I 

11815'115 I I DLG3 I I cU.8CS . 1arue mro.ODU~a) ~10Q" 3 lneuroeDdoerine- dl..a\ II HiID .11101 I I R : 

10.551 II PRJOUB1 • I u1ate1et - oet:lvat::l.Aa" :factor ac::etv1hVdrolaso . iao:form. Xb . a1uhA sUb1anit 
'9'52 II ITDl2 II :Lnter- a1Dha (Ul.ob1l.l.:1.n) i.nJl:lbitor . H2 1;)01vueutid,e II Ks . 1'5285 II R06588 II 
113322 II 1lHGPT1 II -aJUd.ODo1.et.:i.n 1 II Ks.2463 II W8485l> II II 284 
2215051' I I I I I I I I JUl1'88883 I I I I 
1144~' I I PRKCG I I *'*Drote:ln Jd..nase C . aamma. I I Ks . 28'0 II R8'1'14 II II 5582 
1.1..01154 I I I I EST. I I Hs. 2.31150 I' R61'838 I I I I 
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U ...2.. II ESTa . lfeak1v .:urn].ar to hYDothet:1.~ Drote:1.n FLJ20489 DfomD .aJ):1onsl DI.aau:1eJ 
30852115 ACE I I anaiote.-:J.h 1: converting eJlZ~ (peptid.)i'l. - dipe;ptid.ase A) 1 II lis . 2'84169 II 
223802 • I I I I I I I :AA..04610 I I I I 
223112 II II EST. II Hs . 91582 I t ~1'43240 II I I 
105568 I' II HoJno __:1ens cDHll FLJ11982 Us , c10ne HEMBB1001335 , :nRtm s equence II Ks . 1 161'6! 
224'50 I I t I I I I I 11'6341'1 I I I I 
99052 I I RXRG • I ret:l.no1d X receotor . UaJIIIM. I I Ha . 2115550 II li'960'8 I I I I 6258 
11631' II SLC22A1 II soll,lte carr:i.er :fam:i.1v 2 2 lor~c c a t:lo.. tr.an.snorterlo . meJIiler 1 II lis.: 
318452 II I I JfI:mct -=_i.e_ JrR!O.; cDH1l DICf'ZU58Q18220 (:from. c10_ DICFZU586B0220) • IIIRRJl seauenc: 
1101'80 II PELP1 I I Droli ne and. ulutami.c ac:1d rich nuc1e.r Drot.e:1n I I Hs . 21'414' II T5013' II 
105602 I' CG:I: - 85 II CGX - .5 urote:1n II 1Is . 34381''' II R521"3 II :K:DUl0283 II 511U 
221845 II II UJUUUfted urotein .,roduc:t fHo1DQ s~ieftSl . mtoIll aeaueJlCe II 1'- . 215410 II 116291115 I I 
11'115'8 II ZlIF3 ., ••ziJu:: :fiJla:er urote.1.n 3 IA8- 51l II Ks . 15!541'O II U481143 II II ..551 
100521 II SHRP:A II .*srnal.~ nuc:l.ear rjJJonucl..eourote:1.. uol._eut:lde A f' Hs . 11'3255 II R1'0488 I I 
115526 I I SNRP1'8 I I smaJ.l. nuc:~ear r:lhonuc:1eourote1.n 1'8);1)a uol.vueut:1de UUIP anUae:n.\ I I Hs . r 
10.. , .., II GRCA II l.:i.lu!:l.v orthol.ov o:f mo_e aene r1.ch c:::1_ter . A aene II Hs • • 16122 II lUl41'81'16 : 
310128 I' I I P e r:forin . :dQQl se~c 1 I Ks. 41110115 I I lll:01115019 I I I I 
3 0928115 II OXTR II oX)"tt:Jcin r eceptor II 1Is . 2820 II 1lI1215365 II II 5 021 
<O.2Sx 1 >4x 
Fig. A 2.2. Genes up-regulated 2 h post mycolactone treatment. 
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STJIUl4 II "STlIRr -.. coata1aUo 4 • • terol reg1Ilated II 110. UIU II H113U II II 134421 

II "ESTs II 110.1.112" II ",114' II II 

DIIC-IR II t_r .....-or del.ted ill oral caJlCer-related 1 II 110.31'0" II ll451101 II II 11203 

E!O II ent_l.till II 110.2313 II IU2MU II II 215' 

If UUillled.Droteill'Droctw;t Obm s.neal . JIIIIIlseneJCe II Hs.53'" 111H1:J1' II II 

II EST•• HicdtlY sillila:r to cntO JUBB Citro. DroUin. lRlIo-iAteract:iJacr . serbe/Ureoai.ae kiAase 21, [H.~ 

II _ lorotea for _:15lm m.- .....j, _ seq1IOIICe II 1Io.315U II 814351 II II 

II EST. II 1Is.2311" II DM1J22 II II 

II _ orotea 0_ m.- ..,1...1 . _ ........,. II 1Is.1325' II HI"" II II 

_1 II _ .....u coataiAiJla 1 II 110.111' II H23D31 II II ..121 

C140rf111 clr_ 14 ...._ readi... tr_ 1 II 110.151" II U1UMl II II 1.1161 

Il10<:2111' II 1...t.lIetical oroteillllGC21016 II 110.13131 II T"12' II II 215564 

1IGCl.l2" II 1...t.lIeticalarotellllGC1.12" II 1Is.2UM3 II lI024n3 II "lU12 

II II II Ull1133 II II 

II EST. II lis .131114 II UII1255 II II 

_1 II VII .....u-watailliJla orotein 1 II 1Io.355nl II 112''1' II II 1.115' 

1!IU1I33 II 1!IUIU3 oroteill II 1Is.11UI5 II ll42"" II II 23821 

1!IU1554 II mll554 orotea 11110.11161 II W21145 II II 51614 

311135 II II _ ....1... dlIIl: n.J21215 tis . clo.. aU1321. _ ......1ICe II 1Is.164U' " ll455623" " 

"121 I )I) II .utilIIrtia tHatia.to> diseas.1 II IIs.U"l II ll454612 II II 3064 

2221" II _ ....i ... dlIIl n.J313" tis . clOIlO _212"24 . _ ......1ICe II 1Is. 3316U II lI4l2U II II 

311561 'IIIDI1 If tr~ue Drotei.a. Uhe __rue-SDa.lLliJla dmM1Jts, II }(s.2""" II 1lJ143M II II 5"" 

311511 II EST• • _rately siIIilar to D12 .... tm12 oroteb IDXS'I1IE) [II.sopl...) " 110.131061 " 1I1164M 

3112" CGI-14' II CGI-145 urotei.Jt. II Ms.1"32' II 1U15115 II II 51121 

lIUll 1!IU1354 II 1!IU1354 .... __ II IIs.3612 II Uli2l12 II II "25 

1"52:1 11 BST_ . Jfoderate1v riJIilar to llwotll.etical Droteu fLJ2U1I Dbm ...teal fH.A(lie..] II Ks.4331U II . 

22Un ElU2 II eal aiae _1... 2 IC • •1_1 II 1Is.32Ull II UUI235 II II 1.123" 

224331 n.J1I115 II ....t ...tieal orotela n.J11115 II 1Is.1IU' II WI5'21 II II 55231 

1.14031 TG113 II tr._htOlli.... 3 IE ..l ....tide. oroteia-al.tOIIiae-_-.ht...,ltraasl.r_) " IIs.2822 " Nfl 

31.1135 BIX II 1I(I.2-anaciated X .roteill II 1Is.159421 II 1I565213 II II 511 

311151 IIPSl II 1Ie.......-hdlat. SYIIdr_ 1 II lis .13'51 II unM II II 3251 

112234 DIIBl II iUil>la. beta 1 lactiY1a I . actiY1a .. al... DOl....tidel II 1Is.121 II 112115'" ,,3624 

l11U' !!IS II testis deriYed traJlSCri.t 13 LD! _ ..I II IIs.un" II T52325" ,,26136 

3""5 IGII II IIIP-alacose de._.... II 1Is.2Un II W'2518" ,,1351 

113152 CTSZ II cat_ Z II 1Is. 25254' II ll411341 II II 1522 

225941 II _ ....i ... dlIIl: n.J21425 tis. clD.. aL14U2 . _ .....1ICe II 1Is. 3I2131 " 8114222" II 

113593 n.J21111 II .....t ...tical .rotein n.J211n II 1Is.1915 II R54135 II II 11551 

312511 _5 II »-1 IIfID4Il _1.. . ....IOIIilY B. -.or 5 II lis. 2315" II 1I2U'" II ,,25122 

222525 LOC13IUl II ....t.lIetical.roteillBCI1I415 II lis. 294143 II ll4Un2 II II 131611 

221113 DRIL2 II dead n-r /Dr.....Wa) -ll).e 2 lbrig1t .... dead riJIgu) II 110.11431 II Wllll1 II II 1062. 

223394 II II II U'2'195 II II 

11M" SLC!1M II sol.u cvr1er t.u. 21 (fatt. acid. trauDOrter). llellhr 4 II Hs.24"53 II HU504 II II 10" 

389215 II .... saDieas dID. FLJlI641 tis . clue ~pc2'I3'n . JIII8Il senence II Ms.24131 II nn51U II II 

225149 II _ ...,i... dlIIl n.J31.U tis . clo.. NT2Rl2..UOl. _ .....""" II IIs.35112' II W51354 II II 

1.11.1" _1 II IDP-riJIosylatioa lactor 1m... acti..tiau .roteill 1 II 1Is.25514 " ll454556 II ,,5513' 

"nn n.J28"5 II ....tJoetical orotet. n.J2I"5 " 1Is. 5420 II N14521" ,,55611 
221.131 II EST. II lIs.n191 II UI64114 II II 

103151 lCDlIU' II nOllU aeJIe orochlct II Hs.14U" II Y94114 II II t1U 

222122 ltIIP4 II 10Dlill bi_ ...teis 4 II lis . "34 II lI4"n II II 23361 

1.19011 Pml2 II .....ailia 2 IU_r ~ 41 II 1Is.25363 II un6325 II II 5'64 

221M2 CYP2S1 II CYt_ PUI . ....I...uy IIS . ..l .....tide 1 II 1Is.'Ul0 II Wl12l1 II II 29115 

311439 II EST•• _r.tely silIIilar to hJPOtetical protela n.J2MU [I"-> sapi...) [II._i...) " 1Is . 214235 " 

245651 II II II Tll421 II EST II 

100134 rBXII' II F-box oalY ...teill , II IIs . 11151 II N5U36 II II 262" 

lln:n JlSTPI21 II JifSTP121 orot.eia II Hs.3,flU II Hl'l" II linin 

ltll" lPP II ...loid beta (Ml urecvsor enub (orelease .exia-n . llzJr.ei.Rr disease) II )(s.111'" 111M2N' 

1151.14 CUII1 II ealoaia 1 . 1.uI) large ..boit " 1Is. 2515 " H15456 " ,,123 

241293 II II II II EST II 

1.12113 II EST II lis. "215 II U181511 II II 

225"2 I1lBBUP II .tIII>2 lat.rootiaa orotela II 1Is.11.11 II Ul14323 II II 55U4 

1.11115 II 1IICfZP434L01.11 II k_tbeticalo..tela _34L11.11 11110.03195 II T115" II ,,64193 

1.13411 II n.J1.1113 II ....tbetical .rotell n.J1.1113 II 1Is."1.1 II T555" II II "613 

110113 II RPC5 II _ ool_rase ill .. __oit RPC5 II 1Is.21431' II Rl"t: II II 55111 

31nl1 II nu II Fe receotor _1......resseoI 1> B cells II 1Is.2'0331 II 812'" II II 14124 

1146·15 t OIZD II on1tU1\e decarboXYlase uUne 1U1b1tor 11 1Is. 223114 II nJoun 11 II U51t 

114293 lSlIL 111I-acylsulWoaosiae OIIido.rirol... lacid cer__l-lile 11110.264131 II V4151i II ,,2Un 

1.15203 SIIXl4 II ..,rtiM aexta 14 II IIs . 315111 II 11""1 II II 51231 

1"2" ECU15 II ....t.lIetical orotell EC4115 II 1Is.322414 II lIlI"' II II lUU , 

116425 B'IIl'3l1ll b.tYrODWiA...... falllily 3. 1III!IIDel' 1.1 II :tIs.214283 II )(12315 If II l.1.1U 

1145" n.a II iaterle1lk1.a' receotor II Hs . IJ3411 II TKU4 II D.-6 receDtor aluM. cMia II 3510 

UU" Cl40rfll1 II c~ 14 oue. readi_ trille 111 II JfI . 11Ml II n118111 t I II S"U 

314454 SLCn2 II ..lote carrier l...uy , 1__._.xc......rl . isolom 2 II 1Is.341255 II W23611 II II 

225212 1!IU14U II 1!IUIU' orote1s II 1Is.115461 II U""14 II II 5503' 

3"255 II ..., ..teu cloM 23115 DIIIl secnaeace II lIs . lIU91 II Htl855 II II 

3UU4 GI'l2 II G lIrotei..a-cosled. receator kban-bteractor ! II HI.51134 II H1UI15 II 11"15 

31.11" II _ ...,1... _ f1Illl•••U lasert dlIIl elD.. EtlUlII!lIZ 3UU. _ ~ " IIs.1100n " nn" 

3."" RJlRrJ.Pl II RaJ. GTPue act1ntl.u aroteia 1 II 1is.113'01 II mll12 II II 5'15 

318"1 DICl'ZP564FQ13 II ....tbetical ...teill _564F113 II 1Is. 12"53 II 1I"5411 II II 51151 

311411 tIIC" tellUCia C (..-roo11o» II IIs.219114 II U5'''55 " ,,3311 

1 >4x 
Fig. A 1.3. Genes up-regulated 8 h post mycolactone treatment. 
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226262 I I C11or£15 I I chromosome 11 O'W)en r ead.1nu :framEt 1 :1 I I Ha . 121619 ,. All46:1'lOS I f I I !i 
312244 II II EST. II Ms . 386445 • I AIO'6953 II II 
118374 II CSTB 'I cvstatin B (stefiD. Bl II 1bo.69:1 II H22!J19' II I' 1476 
222013 • I KX:JUIo.O'35 II JalUle935 urotein II Hs . 12183 II T'J36'5 II 23324'I 
112'02 II II JfoIRp sapie_ cDIQ FLJ23711 :1::1.• • c10ne HEP123'l1 . ~ :l5eauence II HIl.355279 l ' 
161617 II II EST• . W'eaklv s:i.JTd..1ar to F22G12. S ou rCaeftOrlulbcliti. e1eQ_l rC.e1eu.....l II }Is 
118683 II FCER1G II -Fe: rraament or: l:~ . Jt.iuh a.:r::fiR.i..tv I . receptolt' Lor: a_ ~1~ent1.de 
114861 I I G:ut~ • I GABJHJU receDtor-assoc:iat.ed. urote:l.A II tw . 7'1'19 'I JlA451'1'25 I' I I 1133 
"'1'39 II II JfDmp __:lens cDHll. FLJ30436 fia . eione BRACE20.'OS'l . nRHJl:sea\U!la.c:e II 118 . 35159'1 
31••310 I I RXSC I I ~1v JlDllD10u or: rat a.ncl mouse retiIMJid-:i.ftduc1b1e .er1:ne carbox:;ypept.idaa 
2210.. I' 'DUL I I TH1- J.:l.ke IDrO$CJ'Q~a\ I I JW . 5184 I I llll9"l1'S42 I I I I 5149", 
114419 I I TDlP2 I I **t1,••_ 1nh1llIitoJ:." 0:£ ,..,t~~a.IO:rote;lJUJl*e 2 I' Ita . 6441 I I U.20548 I I I I 
38'108'1 II ..CD II :awo~n . 1:iaht bo~..,.,_t:Lde . recna.atorv. :hDn- sarcomeric 12eu) II Hs.180224 
226:8.8 I I L1UtS I I ~eucv-1-tRHl\ svntheta..e I I ~. 6762 I I lUl'1013'19 I I I I 51520 
101042 I I THRA II thvroid. hornone rece-ot.or . ~uha le:rvtJu:ob1aat:.ic 1eukelnd..a v:l.ra.1. (v- erb- a) 
1.14210 I I ftGC'S248 I I clvn.actin 4 I I Hs .111429 I' R5477, I I I, 845i6 
S08209 II ~0843 II l<XAAO....S Drote.:i.n II lIs.26777 II AA97'1072 II II 22885 
222116 I I ~S23 • I .a.tocbondr1a1 rSboa~ urote:l.n S2S I I ... . 5836 I I JUl488'165 I I II 51649 
1131'16 I. HTD14 II HT014 II lIs.31819 II T539'16 II I. 5'1095 
22281'1 I I TPlIRL • I TPA recnal...t:.ed 10cus I I Jr. . 296510 I I lUl'104860 I I I I 55858 
108284 II YlBGZ II tvro.::t..ne 3-:nunooxvae_e~trVDtODJuuI. 5 - monooxvae.aa.e activ.tion Drotein . 
10'1536 II LOC113201 II hVDOthet:l..ca1 Drotein BC012124 II JiB . 923966 II lUK18825 • I I I 113201 
1.1.903' II RGS.1 II recru1ator 0:£ G - »rote:l...lt. ~an.e.l.1:I.._ .1 II tw . '15256 II lUl017411' II II 5"6 
108'1$4 • I TCEB1 I I tranacr:S:at:i.on e10:rLg'.t:l.o_ :£acto:r B (SI'XX) , Jlo11'»ept:l.de .1 (15Jd>a , e1ong1n 
994'14 I I • I • I I' H80335 II I' 
101'579 I I I. Homo ._:Le~ cI)~ ELJ14.96'1 :r:La . c10ne 'Dtl!:RD10e0242 . :nuderate1y s:lnd.1ar to ZIH 
1121'06 II CGX- 119 II _CGr _ 1..1' »rote:l...lt. II Hs . 28361'0 II H'I8365 II II 51643 
10.04'1 II D1CFZ»66'IB1218 I. ""''''''hvaot.llet:l..ca1 Drote:l..n DB£'Za667B1218 II 1Is . 151293 II R96309 I I 
319'04 II CQIft' I. c.techo:L- O - :methv:Ltr.aJl8:£eraae I. Hs.240013 It 1U016'" II I I 1312 
221318 I I POGZ 1 I 'Doao trAJUnllolil'ab1e e1_~t '9d.th ZHF d.oma:Ln I' .... 101'088 I I llA1''15828 II I I 
221.31' II II UnJuaown, fHI;QnQ .-..ien:s' . 'J1iIRIOl _eaue:ace " J(ai.36.... 810 I. :aAti81'531 II II 
331322 II S180A4 II S100 c:~c1..m. bi.nd.1na D:r;Dte:l..n A4 'ca.1.c:ium. DrDtein . ca1v_cu.1:l.n . :netGStas 
1205'13 I I SHRPF I' ~1 ~uc1ear r:UJo~~eoDrote:Ln Do1vneoticte F I I Hs. 1054.65 I I AA668189 I 
109521 'I JCDlAO,77 I I KrlUlO'1'7 Drote:l..n I I :tis . 300855 I I AA550110 •• • I 2283'1 
225008 I. I I EST. ·. Moderate1v _1m:I..l.ar to h""ll'DOthet:l.ca1 protein FLJ20489 [JfQImo ...:lens) (H • • 
221184 I' I. EST. I I ..... 3555'59 •• H35369 I I • I 
113'03 •• CLTB 11 ~.thr1n. . 1iaht »ol..vaeut.:Ld.e ILcbl II Hs . 380'J49 II H20335 I. I' 1212 
113605 I TFR.C I' tr~:rer:r:i.n :receat;or lD90. CD'I1l ., H:a.7"13156 I. H2132, I I I I "109'1 
104.5"1 PHICB I I "Dhosnhorv-1_e k:I.._e . bet. I I lis. "180150 • I lU:050025 • I I I 525'1 
310411' .P.4R2 II Drouin'Dhosuhat_e 4 . reuu1..torv subunit 2 II "'.356:686 II WB"1465 II 
2204'1 I. -Homo s~:l.e_ JrRHA : eD~ DRFZD3131E1815 (:tr-om. c10ne DICFZp313E1815), ~ seq1&. 
104.264 I I *"'"EST. II ... . 126814 I I lUl'3124"1 • I I' 
1201'25 I I ""''''''EST_ . Hluhl.v .:bn:i.l..ar to COBW-1:l.lte protein [HOmo • .,1.ens] (H . ....:l.ena] IlKs . 
433348 II .......toch . eont . ESTs II • I II II 
108015 • I "'""'"EST • • "Mod.er.te1v s:bld..1e.r to FR.G1 l-flDmH FRG1 urotein lFSHD recd..on. ""ne 1 uro 
226178 MRPS18:' I I mt.tocho.clria3. r:UJosCDllllll.l.. b:rote:l.R S18Ja. I' "' . 9622 • I lUl98326'J • I • I 551 
3083156 II EST&" . "Wee.Jt1v s:i.mi.l..ar to ZK631' . 'Ib . D rCaenorJuibcU.t:l.s e1eg_] (C . e1eg-ans] II Hs 
22'1013 S164 II S164 "Drote:i.n II Hs.180'l8' II 1lA6"1'l6:03 II •• 5851'1 
110191 :ARIfT II arY1 hYdrocarbon :rec:eutor nucl..ear tr-.1Qc.tDr II Hs.1661'12 II T6"1'552 • I 
1108'6 UBE.1 I I **ub:1.c:nd..tin-.activa.t1.na eazvme £1 IA1S9T and. BN'J5 t_rature aens:i.tiv:l.tv 
103'1'6 TXHrP II "'"*t~oreclox1.n :1.nteract:l.._ "Drotein II Jfs.11"526 II lUl931... .,. II II 10628 
226608 II S~ar to LOC16961" fHI;QnQ s_iens' • ~ .ec:nae:ace I I Hs.10'8.7 I I ...634424 I 
118820 •••ZIUB I I 'Drote:U'l "D...,..,Ja.ataae 2 1 ~0~r1v 2)U • reaul._torv .liIblUd.t A II'R 6!n . bet 
226024 1IGC3038 II hYbOtllet1..cal. Drot.ei" e::bId.~e.:r to ect.~ re1.t;..ed 'Drot~ 2~' COI!alI1ex. sub 
111'1'14 II Un.Jcnown IDrotein :£or IHlUiiE:54'5'566'l fHI:Qno __1..e_1 . MRRA secnae:ace II Hs.67'176 
2251'"12 CLXC4 II ch1.or::l.de :U'ltrace11111e.:r chanRel.. 4 II Hs . 25035 II lUl634261 II II 25'32 
104504 PTHJIo I I • .....,rothvmosi.n . al...Dha 1__ .eauence 28l I I Hs. 2!lie655 I I 1lA442'91 J. I I :I 
12:808' CD'6 I I CD36 _t:1._n Ic011aaen t..,.,e X rec_tQr . tJu:-<DItJo~ond.:LA :receutorl I I Jr. . '15 
2221'28 l4RPS6 II m:1.tQchoJUlr1..a1 ~o~ Drot..ein S6 II ~.4241'51 II A1t8,.8.,2 II II 64'6_ 
1810"10 HDlIP1UI1' I IOlOK dehVdrQoe_ l"Ubiau:i..nonel 1 . a.1."Dha.~et.. subccmm1ex . 1 . 8Ja)_ II K 
1060:16 I I EST• • "Wee.Jt1v sbTd.1ar tQ IUtG4 JtIJImH RlLo-GTP_e - activa.t:l.ncr "Drot.e:!.n 4 litho - GAP h 
301'61'5 C:"ZiU. II C:.a:a»inu urotein la.ct:U'l t.i.1.-nentl muscl..e Z - 1:l.ne . al."DJut. 1 II Hs.18421'0 II 
222036 KACF1 II m:l.crQtulna.e-actin cros_1:I..n.k:I..nU rac:tQr 1 II Hs.108258 II lUl.2'181"10 II II 
186628 I I HoIno __iens eD~ FLJ10004 U. . c10fte HEMBA10800'l6, II"RH1l sequence II lis. 38120 
101488 I I EST. I I HIII' . 2'6272 I I JliU.43342 I I I I 
226681 ~IUB1 II al..do - ketQ reductase :£amd..1v 1 . member B1 l~cIo.e red.uct_e~ I. Hs . 1'53i3 
110648 I I Homo • ..,ie_ nRNA: eDNA J)1CI!'z.,586X0324 1 rrom c1Q.fte DI<FZD586X0324l • J"I'RHA IIcquen 
'9'49 I E11.1 I I llvaQt.het:l.cal. »rot.e1n £11.1 I I HIs. 7913 •• llll436481 I I II 222166: 
113514 I I I I CGX - 9' "Drote1n I I Hs. 110803 I I lUl463512 I. • I 5163'1CGJ:-" 
113335 II 1UU1311 II RliB3A . ~er RAS Qnco--.e r.-.:i.1v II )fa.21'1'44 II H14230 II II 5864 
103615 I I I I U~ "Drote;Ln »rodv.c:t nfoIno _ie_1 • ~ sequence I. :tis . 3"11'1''55 I I )Uk6340e 
22:121' I' PPllLH1 I I _r1DlII1..1:i.n 1 I I 1Is.281428 II AA6"'l'l361 I I I I 51535 
128761 I I ICIllAQ"1Q1 I J lCXAA8'101 DrQt.e1:n. I I :tis . 1'53293 I I H2'596 I I I I 230'14 
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IDENTIFICATION OF THE TARGET/S OF MYCOLACTONE
Introduction
In this chapter, the use of two different approaches to identify the target of mycolactone
is described: a genetic approach using yeast, and a biochemical approach using
fluorescently tagged mycolactone.
Interest in using a genetic approach to identify the target ofmycolactone resulted
from extensive studies published in the past two decades describing use of the yeast
Saccharomyces cerevisiae as a model system to gain valuable insights into the targets and
modes of action ofa diverse array of drugs (119, 129-131). Genetic and molecular studies
in yeast have demonstrated that the drugs FK506 and cyclosporine inhibit growth via
immunophilin dependent inhibition of fungal calcineurin (116, 129). The target of the
FKBP12/rapamycin complex was also first identified in yeast as the TOR (target of
rapamycin) kinase homologues (130). In higher eukaryotes, the immunosuppressive
macrolide compounds cyclosporine (CsA), FK506, and rapamycin inhibit the
intermediate steps in signal transduction between the cytoplasm and the nucleus. These
three compounds are immunosuppressive because they block signal transduction
pathways required for activation of helper T cells. FK506 and rapamycin are related
macrolides and share no chemical similarity with CsA, a cyclic undecapeptide (119, 131).
Recent studies revealed that the molecular mechanisms of the immunosuppressive and
antimicrobial effects of FK506 and rapamycin were remarkably similar and involved
inhibition of highly conserved target proteins (37, 39). Both drugs are hydrophobic and
enter the cell by diffusion. They then bind to highly conserved intracellular protein,
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FKBPI2, which is conserved from unicellular eukaryotes such as S. cerevisiae to man.
FKBP12 is an enzyme that catalyses cis-trans peptidyl prolyl isomerization, a rate-
limiting step during protein refolding in vitro (130). Both FK506 and rapamycin bind to
the FKBP12 active site and inhibit activity, but this is not the mechanism by which these
drugs act. Instead, the protein/drug complexes are the active in vivo agents (37,39). It
was observed that yeast mutants lacking FKBP12 are viable and resistant to FK506 and
rapamycin and increasing FKBP12 protein levels in mammalian cells by transfection
results in increased drug sensitivity. The target ofFKBP12IFK506 complex is calcineurin
(119, 131). Calcineurin is a calcium/calmodulin activated protein phosphatase that plays
a central role in signal transduction from the T-cell receptor to regulate T-cell activation
and plays diverse roles in yeast involving gene regulation and cation homeostasis (115,
123). The target of the FKBPl2/rapamycin compex is the TOR (target ofrapamycin)
kinase homologues (119, 124, 130-131). The success met by researchers in identifying
the targets of the macrolides by using yeast as a model organism led us to use a similar
approach to investigate the target of mycolactone.
Use of yeast as a model system to identify the target of mycolactone
To detect the effect (cytopathic/cytostatic) of mycolactone on yeast, a variety of
strains were used. Strains used and their sources are listed in Table 7. The strains tested
included 4 strains of S. cereviceae and 2 strains of Cryptococcus neoformans kindly
provided by Dr. Joseph Heitman (Duke University Medical center, Durham, NC).
SMY47-9.ld and SMY76-13b are SMY44-1 derivatives. MLY61a/u is a diploid strain
with L1278b background. JEC21 is of serotype D and is avirulent whereas H99 is of
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serotype A and is virulent. The C. neoformans strains were sensitive to rapamycin,
FK506 and CsA while S. eerevieeae strains are sensitive to rapamycin (116). In addition
to the strains mentioned above, C. albieans SC 5364 and S. eerevieeae BY4742 provided
by Dr. Jeffrey Becker's lab at the University of Tennessee, Knoxville were also tested for
sensitivity to mycolactone. Sensitivity to mycolactone was tested by disc diffusion
method as well as broth dilution method.
Materials and methods
Disc diffusion method: S. eerevieeae, C. neoformans and C. albieans were
cultured in YEPD (Difco) liquid medium overnight at 30DC (S. eerevieeae, C. albieans)
or 37DC (c. neoformans). Cells were pelleted and resuspended in fresh culture medium at
5xl06 cells/ml. Yeast cells (lml) were added to 2 ml of 0.2% noble agar which was
poured onto the surface ofYEPD or minimal agar (with amino acid supplements and
uracil) medium and allowed to solidify to allow even distribution of inoculum. Paper
discs (6.35mm, Becton and Dickinson, Cockeysville, MD) were placed on the agar
surface and different concentrations of mycolactone (50 f-Lg, 5 f-Lg, 1 f-Lg, 500 ng) were
added to discs, ethanol served as negative control. Plates were incubated at 30DC or 37DC
for 24-72 h. Growth inhibition was quantified by measuring the distance from the edge of
the disc to the zone of growth (the radius of growth inhibition).
A similar assay was repeated by making YEPD plates with the above
concentrations of mycolactone added to the agar before pouring the plates. Yeast strains
were streaked onto plates and observed after 24, 48 and 72 h for growth inhibition.
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Table 7. Yeast strain list.
Strain used Description Source
S. cerevisiae SMY44-1 (Mata trp1 his3 ura3 60pS- Joseph Heitman
LEU2)
S. cerevisiae SMY47-9.1d (Mata trp1 his3 ura3 60pS- Joseph Heitman
LEU2 erg6)
S. cerevisiae SMY76-13b (Mata trp1 his3 ura3 60pS- Joseph Heitman
LEU2 erg6 pdr5 snq2)
S. cerevisiae MLY61a/a (Mata/a ura3-52/irra3-52) Joseph Heitman
S. cerevisiae BY4742 (Mata His.6. Leu.6. Lys.6. Ura3) Jeff Becker
C neoformans JEC21 Joseph Heitman
C. neoformans H99 Joseph Heitman
C. albicans SC5364 Jeff Becker
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Broth dilution method: Broth dilution method was set up according to the NCCLS
reference method for antifungal susceptibility testing for yeasts (132). Briefly, 0.1 ml
yeast strains was added to O.lml YEPD or RPM! medium with different concentrations of
mycolactone (lOng, 100 ng, SOO ng, 1000 ng, 7.9 f-lg) in a 96-well plate. Ethanol was
used as a negative control. Inoculum was prepared from 24 h (S. cerevisiae, C albicans)
or 48 h (C neoformans) cultures at a concentration of Sxl02 to 2.Sxl03 cells/ml. Plates
were incubated at 3SoC for 46-S0 h (C albicans, S. cerevisiae) or 70-74 h (C
neoformans). Growth in each well was compared to growth in ethanol treated and control
wells. Plating samples showed that there was no inhibition of growth by mycolactone as
the number of viable yeast was the same between the test and control groups.
Results and Discussion
A sensitive phenotype was not found in the yeast strains used as there was no
inhibition of growth ofall strains tested by either the disc diffusion method or broth
dilution method. The possible reasons as to why we did not see a sensitive phenotype in
yeast that were tested could be because the target for mycolactone may not be present in
yeast. Another possibility is that mycolactone may not be able to enter the yeast cell in
the same way as other macrolides like rapamycin and FKS06 do. In the future, one way to
test this would be to use fluorescently tagged mycolactone to visualize the permeability
ofyeast cell wall to mycolactone.
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Biochemical approach to identify the target of mycolactone using fluorescent
mycolactone analogs
An alternative approach taken to identify the target of mycolactone was analysis
of the interaction ofL929 fibroblast cell proteins (cytosolic and cell membrane proteins)
with fluorescent mycolactone analogs. L929 fibroblast cells were used because they are
sentitive to mycolactone and the cytopathic effect ofmycolactone on these cells has been
well studied (35, 36). Structures of the fluorescent mycolactone analogues are as shown
in Fig. A 2.1. The fluorescent analogues were kindly provided by Dr. Michael Burkart at
the University of San Diego, CA. Both the analogs were cytopathic to L929 cells though
the cytopathicity was roughly 100-fold less than that of the native myctoalctone.
Materials and methods
Cytoplasmic and cell membrane proteins were isolated from L929 cells as
follows. After growing confluently for 48 h, cells were washed three times with 10mI of
sterile PBS (pH 7.4), and centrifuged at 5000 rpm (10 min, 4°C) between each wash. Cell
pellets were then frozen at -20°C for 3 h after which they were resuspended in 10ml of
ice cold HB-I buffer (250mM sucrose and 3mM imidazole, pH 7.4) and pelleted at 5000
rpm (5 min, 4°C). The resulting pellet was suspended in 5ml HB-2 buffer (250mM
sucrose, 3mM imidazole, 0.5mM EDTA, 0.5mM PMSF, pH 7.4). The pellet was passed 5
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Fig. A 2.1. Structure of fluorescent mycolactone analogues 14 (A) and 17 (B). 
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at 1500 rpm (5 min, 4°C). Supernatant was removed and recentrifuged at 68,000 g (30
min, 4°C). After centrifugation, the supernatant that represents cell cytosol proteins was
pooled and the remainder of the pellet that represents the cell membrane proteins was
resuspended in 5ml ofHB-2 buffer with 1% Triton-X 100 (Sigma). The resulting proteins
were stored at -20°C.
To determine mycolactone-protein interactions, proteins were preincubated with
fluorescent mycolactone analogs and separated on a native gel. Alternatively, proteins
that were separated on native gels were incubated with fluorescent mycolactone analogs
and checked for the appearance of a fluorescent band on the gel. Proteins were incubated
with different concentrations of (5 ng, 25 ng, 100 ng, 1000 ng) of the fluorescent
mycolactone analogues for 15 or 30 minutesat room temperature in the dark. After the
incubation period, proteins were loaded onto a native 12% polyacylamide gel and run for
1-1.5 h at 20mA. The gel was observed under ultra violet light to identify the presence of
a fluorescent band.
Results and discussion
Specific fluorescent protein bands different from the control lane were not
observed. The presence of non-specific bands on the gel in the control (fluorescent
mycolactone analogues) lanes similar to those found in lanes in which proteins
preincubated with fluorescent mycolactone analogs were run revealed that it would be
difficult to identify a particular protein to which the fluorescent mycolactone binds using
this approach. Similar results were obtained when cytosolic proteins or cell membrane
proteins were used. When proteins separated on a gel were incubated with different
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concentrations of the fluorescent mycolactone analogues for 30 min, 1 h or overnight,
specific bands could not be found. A major pitfall was that mycolactone seemed to bind
all over the gel, non-specifically, and the whole gel was fluorescent.
Preliminary studies with fluorescent imaging ofL929 cells incubated with
fluorescent mycolactone analogs showed that the molecule is localized in the cytosol and
does not enter the nucleus. In the the future, one way to investigate the specific
localization of mycolactone in the cytosol would be to use fluorescent dyes to stain the
different compartments of a cell and use the fluorescent mycolactone analogues as tools





Mycolactone was isolated originally from M uicerans 1615, a Malaysian isolate,
as a mixture of cis/trans isomers designated mycolactone A and mycolactone B (34).
Cadapan et al. have recently shown that M uicerans 1615 produces several minor species
of mycolactone (congeners) in addition to mycolactoneAIB which differ primarily in the
number of hydroxyl groups and double bonds (75). While mycolactone AlB is the
dominant species from African isolates, mycolactone C is the dominant mycolactone
species from the Australian isolates. Mycolactone C is a variant of mycolactone AlB with
an altered side chain due to the absence ofa hydroxyl group at C12' position (Fig. 7.1).
Mycolactone C has been shown to be 10,OOO-fold less cytopathic than mycolactone A
and B (3). As shown in Fig. 1.1 (introduction), the structure ofmycolactone consists ofa
core and a side chain. The mycolactone core lactone is encoded by misA and the fatty
acid side chain by mZsB (42). Previous Mve-obiang et aZ. have shown that the core
lactone is sufficient for cytotoxicity, although it is much less potent than the complete
mycolactone (3).
Since mycolactone occurs as a mixture of isomers in nature, it is difficult to
attribute the cytopathic effects of the toxin to any single species of mycolactone. In order
to study the contributions of each isomeric species of mycolactone, chemically
synthesized mycolactones A, B, C, core and side chain were used. These chemical
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Fig. A 3.1. Structures of mycolactone NB (A) and C (B). (Taken from 
Judd, T. c., et ai. 2004) 
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analogues were provided by Dr. Yoshito Kishi at the Department ofChemistry and
Chemical biology, Harvard University, Cambridge, MA. Cytotoxic effects of the
chemical analogues in terms of differences in necrotic and apoptotic effect of the toxins
were investigated.
Results and discussion
Necrosis and apoptosis assays with chemically synthesized analogues of mycolactone
Apoptosis and necrosis assays were performed as described earlier in materials
and methods in Chapter 2. L929 fibroblasts (6x103 cellslml) in a 96-well plate were
treated with two different concentrations of the chemical molecules or native
mycolactone as specified in Fig 7.2 (A, B) or an equal volume of ethanol. After 24 and 72
h, cells were tested for apoptosis and LDH release. Native mycolactone extracted from
M ulcerans grown in the laboratory caused apoptosis as early as 4 h at high
concentrations (15 Ilg) whereas low concentrations caused apoptosis only after 24 h.
Mycolactone C showed a similar apoptotic effect as mycolactone (15 ng) at 4 as well as
24 h time points. Side chain and core showed very little apoptotic activity after 4 and 24
h. The cytotoxicity profile as measured by LDH release was the same for all the chemical
derivatives and native mycolactone added at a concentration of 15 ng. Similar results
were obtained when higher concentrations were added with all the analogues exhibiting
an increase in cell wall permeability at 4 h as well as 24 h. Mycolactone C was added at a
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Fig A 3.2. Necrosis (A) and Apoptosis (B) of L929 fibroblasts 4 and 24 h 
post treatment with chemically synthesized mycolactone core, side chain, 
mycolactone C and native mycolactone. 
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In another set of experiments, chemically synthesized mycolactone A and B were also
tested for ability to cause necrosis and cell death. In addition, a mix of mycolactone A
and B at a ratio of 3: 1 was used to see if the mix could behave like the native molecule
which occurs in nature as an isomeric mixture of mycolactone A and B in a similar ratio.
No difference was observed amongst the tested groups other than at the 24 h time point
where native mycolactone at a concentration of 100 ng caused more necrosis than the
other derivatives (Fig. A 3.3). There was a significant increase in the amount of apoptosis
caused by mycolactone B on day 1 at 100 ng concentration when compared to
mycolactone A or mycolactone AB and was similar to native mycolactone molecule. By
48 h the cells had undergone significant amount of apoptosis when derivatives were
added at a concentration of 100 ng or 1000 ng.
Though most isolates of m. ulcerans produce mycolactone AlB. Mve-Obiang et
al. showed that there is considerable heterogeneity in the mycolactone congeners
produced by strains from different geographical areas. Although the biological activity is
conserved, these molecules have been shown to differ in potency (3). The same
researchers showed that the core lactone of the toxin is sufficient to cause cytopathicity.
Similar results were observed in the presernt study where the chemical core lactone
analogue was sufficient to cause necrosis. Mycolactone B caused more apoptosis than
mycolacone A. The cytopathic effect of mycolactone A seems to be due to necrosis. It
was interesting to find that the side chain also caused necrosis at levels equivalent to the
core and native mycolactone. Though mycolactone C was added at a lower concentration
than the other analogues, its activity was similar to native mycolactone. Further
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Fig. A 3.3. Necrosis (A) and Apoptosis (B) of L929 fibroblasts 1 and 2 d post 
treatment with chemically synthesized mycolactone A, B and native mycolactone. 
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experiments at varying time points using different concentrations may yield an insight
into the contribution of each isomer to the activity of native mycolactone.
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